



Scientific  
**Sessions**

**NOVEMBER 5-7, 2022**  
CHICAGO, IL + VIRTUAL



American  
Heart  
Association.

# On-Site Meeting Guide

#AHA22  
[ScientificSessions.org](https://www.scientificsessions.org)

DON'T MISS  
A BEAT 

## See Inside For:

- Main Events
- Late-Breaking Science
- Pre-Sessions Symposia  
and Early Career Day
- Heart Hub
- Networking  
and Engagement
- Case Theater
- Exhibitor Details  
and Products/Services




Also see inside for key wayfinding maps ►

# elucidVIVO™

## Solving the Heart Attack Crisis with Next-Generation Plaque Analysis

ElucidVivo with PlaqueIQ™ Technology is a comprehensive, non-invasive CTA plaque analysis software that accurately identifies a patient's complete vascular profile – directly identifying plaque tissue types inside the vessel wall that may cause rupture.



**Join Us in the Heart Hub:  
Learning Studio 2**  
Saturday, Nov. 5<sup>th</sup>  
3:00PM – 3:45PM

### Pioneering the Future of FFR<sub>CT</sub> Powered by PlaqueIQ™ Technology

Scan the QR Code to view a recent publication in the International Journal of Cardiology.<sup>1</sup>

[Learn more at Elucid.com](https://www.elucid.com)



1. Vargas-Szemes, et al. Coronary plaque assessment of Vasodilative capacity by CT angiography effectively estimates fractional flow reserve. International Journal of Cardiology. Volume 331, P307–315, May 15, 2021.

\*CAUTION: Limited by United States law to Investigational Use.  
© 2022 Elucid. All Rights Reserved. ElucidVivo and Plaque IQ are trademarks of Elucid.

This event is not part of the official Scientific Sessions Conference 2022 as planned by the AHA Committee on Scientific Sessions Programming.

# elucid™



Scientific  
Sessions



# Visit the Heart Hub

At the heart of the Science & Technology Hall,  
explore these useful learning and  
networking opportunities



**HeartQuarters**

**Learning Studios**



**Health Innovation  
Pavilion**

**Heart  
Theaters**



**Braindate  
Lounge**

**Get With  
The Guidelines®  
Quality Showcase**

**Recharge Lounge  
Sponsored by Sanofi**

**Headshot Lounge  
Sponsored by  
Bristol Myers Squibb**

**Early Career/  
FIT Lounge  
Sponsored by Kiniksa**



**FAHA  
Lounge**

**Go Red Women in  
Science & Medicine Lounge  
Sponsored by Janssen**



**ScientificSessions.org**  
**#AHA22**



# A home for all things health technology at Scientific Sessions.

Visit the **Health Innovation Pavilion**, located in the Heart Hub. Attend the 3-day Health Tech & Innovation Summit and engage with companies and start-ups showcasing their products and services.

- Health Tech Competition
- Early career and technology – rise of the “doctrepneur”
- Strategically focused research network for health technology – the DOT.HF study
- Life’s Essential 8 and the Intelligent Health Solutions
- Doctors with Heart
- Beyond the cuff: Novel metrics and digital therapeutics
- Technology of tomorrow
- Exercising in AFib
- The women of health technology

## Join us for the 2022 Health Tech Competition

### Competition Days

Day 1: Health Tech Competition

Date: Nov. 5, 2022

Time: 1-2 p.m.

Location: Health Innovation Pavilion

Day 2: Health Tech Competition

Date: Nov. 6, 2022

Time: 11:30 a.m.–12:30 p.m.

Location: Health Innovation Pavilion

Watch as finalists pitch their health tech start-up to top physicians, industry leaders and VIPs who can help take companies to the next level.



### 2022 SPONSORS

#### Platinum Supporter



#### Gold Supporters



XANDAR KARDIAN



American Heart Association. Doctors With Heart



#### Silver Supporters



# Inside



All times noted are Central Time.



**8**  
**Message From the Chair**  
 Manesh R. Patel, MD, FACC, FAHA

**10**  
**Main Events**

**14**  
**Late-Breaking Science**

**13**  
**Presidential Session**

- 13** Presidential Session
- 20** Programming Communities
- 21** Livestream and On-Demand

**Friday Programming**

- 22** Early Career
- 24** Frontiers in Science
- 24** State-of-the-Art Cardiovascular Care
- 25** Congenital Heart Research and Innovation
- 25** Heart / Kidney Symposium

**Special Focus Programs**

- 2** Health Tech & Innovation
- 26** Health Equity
- 28** Precision Medicine
- 29** Women in Science & Medicine

**65**  
**Braindate at Scientific Sessions**



**American Heart Association**  
 National Center  
 7272 Greenville Ave.  
 Dallas, TX 75231  
 224-373-6300 | 800-242-2453  
[professional.heart.org](http://professional.heart.org)

© 2022 American Heart Association.  
 All rights reserved.

Publishing partner for Scientific Sessions 2022:  
 Ascend Media LLC  
 401 SW Ward Road, Suite 210  
 Lee's Summit, MO 64081  
[ascendmedia.com](http://ascendmedia.com) | 913-469-1110

Ascend Media encourages and practices environmentally friendly printing, including recycled/recyclable paper and plant-based inks.

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions. Data current as of Oct. 14, 2022.

**Exhibitors**

- 40** Exhibitor information
- 48** Exhibitors by Community
- 50** Product Categories
- 53** Exhibitors by Booth



**1**  
**Heart Hub**

**54** Science & Technology Hall Map

- 30** Learning Studios
- 31** Roundtables
- 32** HeartQuarters
- 60** Symposia Schedule
- 63** Thanks to Our Supporters

**58** McCormick Place Map

- 56** Key Locations
- 57** Shuttle Bus Schedule



# In-Person Schedule at a glance

#AHA22

	FRIDAY November 4	SATURDAY November 5	SUNDAY November 6	MONDAY November 7
6:00 AM CST 8:00 AM CST		Satellite Events	Satellite Events	Satellite Events
8:00 AM CST 12:00 PM CST	Early Career Programming	<b>Opening Session</b> Main Events Late-Breaking Science Concurrent Programming Science & Technology Hall 9 a.m. - 4:30 p.m. HeartHub Industry Events Meet the Trialist	Main Events Late-Breaking Science Concurrent Programming Science & Technology Hall 9 a.m. - 5 p.m. HeartHub Industry Events Meet the Trialist	Main Events Late-Breaking Science Concurrent Programming Science & Technology Hall 9 a.m. - 3 p.m. HeartHub Industry Events Meet the Trialist
12:00 PM CST 6:00 PM CST	Early Career Lunch with Legends Congenital Heart Research & Innovation <b>Frontiers in Science:</b> • Atherosclerosis, Thrombosis and Vascular Biology • Arrhythmia Research Summit • Vascular Disease Heart/Kidney Symposium State of the Art Cardiovascular Care	Main Events Late-Breaking Science Concurrent Programming Science & Technology Hall HeartHub Industry Events Meet the Trialist Health Tech Competition	<b>Presidential Session</b> Main Events Late-Breaking Science Concurrent Programming Science & Technology Hall HeartHub Industry Events Meet the Trialist Health Tech Competition	Main Events Late-Breaking Science Concurrent Programming Science & Technology Hall HeartHub Industry Events Meet the Trialist
6:00 PM CST 9:00 PM CST	Satellite Events	Satellite Events AHA Member Celebration Council Events	Satellite Events	Satellite Events



**Compete in the #AHA22 scavenger hunt to win prizes!**

For more details, use the QR codes below to download the Mobile Meeting Guide app.



Mobile Meeting Guide App sponsored by:



Google Play and the Google Play logo are trademarks of Google LLC. Apple and the Apple logo are registered trademarks of Apple Inc.



On Demand Access | Early Career & FIT | Women in Science & Medicine Sessions

Networking Lounges, Activities, Braindate



# Virtual Schedule at a glance

#AHA22	FRIDAY November 4	SATURDAY November 5	SUNDAY November 6	MONDAY November 7
6:00 AM CST 8:00 AM CST		Satellite Events	Satellite Events	Satellite Events
8:00 AM CST 12:00 PM CST	Early Career Programming	<b>Opening Session</b> Main Events Late-Breaking Science Industry Events	Main Events Late-Breaking Science Industry Events	Main Events Late-Breaking Science Industry Events
12:00 PM CST 6:00 PM CST	Congenital Heart Research & Innovation	Main Events Late-Breaking Science Industry Events Meet the Expert	<b>Presidential Session (1 PM)</b> Main Events Late-Breaking Science Industry Events Meet the Expert	Main Events Late-Breaking Science Industry Events Meet the Expert
6:00 PM CST 9:00 PM CST		Satellite Events	Satellite Events	



**MAKING A DIFFERENCE**  
INVESTMENT IMPACT



More than  
35 million  
**DONORS,  
SUPPORTERS  
AND VOLUNTEERS**

ePosters | Exhibits | OnDemand Content



# Welcome to #AHA22



**Manesh R. Patel, MD, FACC, FAHA**  
Chair, Committee on Scientific Sessions Program

Dear Colleagues:

It is my great pleasure to welcome you to the American Heart Association's Scientific Sessions 2022. This year's meeting centers on renewed connections and passionate discussions on the year's most ground-breaking updates in the fields of cardiovascular clinical, basic and population science.

Regardless of your location, you have the opportunity to participate in group discussions and debates, engage with interactive sessions featuring cutting-edge topics across an array of specialties, and meaningfully connect with peers, mentors and friends from around the world.

The scope and quality of the scientific exchange is what makes AHA Scientific Sessions the premier cardiovascular research and instructional meeting in the world.

- Watch as the most highly anticipated breakthroughs in patient care are announced during Late-Breaking Science sessions.
- Immerse yourself in cutting-edge CV science topics during our Main Event sessions.
- Stay on top of the latest trends in health care technology with the 3-day Health Tech Summit.
- Over 400 sessions including sub-specialty and cross-specialty programming, and 4,000 abstracts!
- For attendees who are not fully vaccinated, proof of a negative COVID-19 test will be required to attend the AHA's Scientific Sessions 2022 in-person at the McCormick Place and any other official event locations in Chicago.
- Connecting with colleagues has never been easier with many hours of featured networking events.

Sincerely yours,

**Manesh R. Patel, MD, FACC, FAHA**  
Chair, Committee on Scientific Sessions Program



*Please join in on the conversation happening online by following #AHA22.*

*I can't wait to see you there!*



PAID ADVERTISEMENT

A Medscape **LIVE!** CONFERENCE

CME

# Advances in Imaging and Targeted Management for Cardiac Inflammation Clinical Progress in Pericarditis

**SUNDAY, NOVEMBER 6, 2022 | 6:00 PM – 7:30 PM CT**

**REGISTRATION AND MEAL: 5:30 PM CT | PRESENTATION: 6:00 PM CT**

HYATT REGENCY MCCORMICK PLACE, 2233 SOUTH DR. MARTIN LUTHER KING JR. DRIVE  
CHICAGO, ILLINOIS 60616 | PRAIRIE ROOM



## MODERATOR



**Allan L. Klein, MD, FRCP(C), FACC, FAHA, FASC, FESC**  
Professor of Medicine  
Lerner College of Medicine,  
Case Western Reserve University  
Director, Center for the Diagnosis  
and Treatment of Pericardial Diseases  
Department of Cardiovascular Medicine  
Heart, Vascular and Thoracic Institute  
Cleveland Clinic  
Past-President, American Society of Echocardiography  
Secretary/Treasurer, National Board of Echocardiography  
Cleveland, Ohio, United States

## PANELISTS



**Paul C. Cremer, MD**  
Associate Director  
Cardiovascular Medicine Training Program  
and Cardiac Intensive Care Unit  
Cleveland Clinic  
Cleveland, Ohio, United States



**Massimo Imazio, MD, FESC, FHFA**  
Head of Cardiology  
Contract Professor of Cardiology  
Cardiothoracic Department  
University Hospital Santa Maria della Misericordia  
Azienda Sanitaria Univesitaria Friuli Centrale  
(ASU FC)  
Udine, Italy



**Brittany N. Weber, MD, PhD**  
Associate Physician  
Cardio-rheumatology Program  
and Cardiovascular Imaging  
Brigham and Women's Hospital  
Instructor of Medicine  
Harvard Medical School  
Boston, Massachusetts, United States



For more information and to register visit

[www.medscape.org/symposium/advances-recurrent-pericarditis](http://www.medscape.org/symposium/advances-recurrent-pericarditis)

This event is not part of the official Scientific Sessions 2022 as planned by the AHA Committee on Scientific Sessions Program.

Supported by an independent educational grant from Kiniksa Pharmaceuticals.

the heart.org

Medscape  
EDUCATION



# Main Events

From the Opening to the Closing Session, the Main Events highlight the best of the best breakthroughs in cardiovascular health, introduce distinguished researchers, lay out the hottest topics and tackle controversies head-on.

## **Opening Session: Moving Science Into Public Health: Lessons Learned**

**Nov. 5 | 8-9 a.m. | Main Event I**

U.S. Surgeons General and International Public Health Experts.

## **The Main Event: Changing Clinical Practice**

**Nov. 5 | 9:30-10:30 a.m. | Main Event I**

This promises to be a celebratory can't-miss first LBS session as we come together in Chicago. Prepare for impactful trial results that are sure to challenge current clinical practices in preventing cardiovascular disease (PROMINENT), treating heart failure (Transform-HF) and managing hypertension (DCP).

## **Annual Dr. Nanette K. Wenger Research Goes Red® Award for Best Scientific Article on Cardiovascular Disease and Stroke in Women**

**Nov. 5 | 11 a.m.-12 p.m. | Main Event II**

The Dr. Nanette K. Wenger Award is awarded by the AHA's Research Goes Red® program,

which aims to empower women to contribute to health research. Collectively, we can unlock the power of science to find new ways to treat, beat, and prevent heart disease in women. This collaboration unites AHA heart health experts, patients and loved ones to truly make a difference.

## **Global Innovations to Transform the Medical Workforce: Addressing Unmet Cardiovascular and Other Health Needs**

**Nov. 5 | 11 a.m.-12 p.m. | Main Event I**

This moderated panel discussion explores challenges and strategic opportunities in the education domain, particularly pertaining to creating and preparing our workforce to equitably address the social, economic and health needs of diverse populations. Panelists will also discuss novel workforce initiatives especially at their respective institutions aimed at transforming the medical workforce.

## **Visualizing COVID for the Long Haul: Heart-Vasculature-Brain**

**Nov. 5 | 11 a.m.-12 p.m. | Main Event III**

This session reflects the dawning realization that COVID will be with us for the foreseeable future. Thus, recognition of its myriad impacts on major organ systems is paramount.

## Distinguished Scientist Lecture

Nov. 5 | 3-4 p.m. | Main Event III



### Distinguished Scientist: Suzanne Oparil, MD

*Photo courtesy of UAB Medicine*

Dr. Oparil is a cardiologist with a special interest in the fundamental mechanisms of cardiovascular disease

and development of novel treatments. She has made many groundbreaking observations in clinical medicine and continues to influence novel treatments for hypertension. Early in her career, she observed that angiotensin-converting enzyme (ACE) was capable of generating a vasoconstrictor hormone, angiotensin II. The work of Dr. Oparil and colleagues led to the development of ACE inhibitors. She identified endothelin as a major mediator of hypoxic-mediated pulmonary hypertension in animal models, a discovery that led to the development of endothelin receptor antagonists for the treatment of patients with pulmonary hypertension. Her recent research has led to important clues about how female sex hormones protect blood vessels.

## Not Your Father's Heart Disease: Microvascular Coronary Function and Its Contribution to Disease

Nov. 5 | 3-4 p.m. | Main Event II

This session highlights the small(er) vessel pathophysiology increasingly recognized, particularly in women. Microvascular coronary disease participates in the pathogenesis of many commonly encountered cardiac problems. The focus of talks will be on how imaging can provide insight into pathogenesis and risk in addition to making the diagnosis of microvascular disease.

## Identifying and Practicing Emerging Genomic-Based Therapies on Cardiovascular Disease

Nov. 5 | 4:30-5:30 p.m. | Main Event III

The rapid progress of genomic profiling in humans and model systems provides new insights into understanding mechanisms of cardiovascular disease. This *ATVB Journal* session introduces genomic-based

therapies promising therapeutic strategy for cardiovascular disease. Many of the targets introduced here have been in clinical trials or successfully applied into humans.

## One Brave Idea – Redefining Coronary Heart Disease at the Edge of Wellness

Nov. 5 | 4:30-5:30 p.m. | Main Event I

It has been six years since One Brave Idea, a research initiative co-founded by the American Heart Association and Verily, with significant support from AstraZeneca and pillar support from Quest Diagnostics, was launched. One Brave Idea was a transformational idea to challenge the way research was traditionally done, through unconventional scientific approaches, to result in major advances in the fight against heart disease.

## Implementing the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization Into Real-World Practice

Nov. 5 | 4:30-5:30 p.m. | Main Event II

Take a deep dive into key points of the ACC-AHA Guideline for Coronary Revascularization. This session discusses key issues related to coronary revascularization and a clinical case to weave real-world issues into guideline recommendations.

## Implementing Machine Learning for Precision Care: Crossing the Bridge to Reality

Nov. 6 | 8-9 a.m. | Main Event II

The session identifies applications of machine learning and data science to broad domains of cardiovascular care, focusing on translating technology to routine clinical care and exposure of disparities by the COVID-19 syndemic.

## Controversies In Valvular Heart Disease

Nov. 6 | 8-9 a.m. | Main Event II

As innovations in transcatheter technologies continue to advance, more patients fall under gray areas of treatment options within surgery and interventional cardiology. This event examines myriad VHDs, including ischemic mitral regurgitation, tricuspid regurgitation, aortic insufficiency and aortic stenosis to examine cutting-edge treatments and current controversies in care management.



## NEW! Headshot Lounge

*Located in the  
Heart Hub*

Bring a friend to take the ultimate selfie or get a new professional headshot.

*Sponsored by*



# Main Events



## Fireside Chats

Continue the conversation of research and science with conference attendees! Each non-accredited chat brings together perspectives from across the research community, enabling real-time discussion of challenges and potential solutions.

View the *Mobile Meeting Guide* app for details.

### Nobel Laureate Lecture

Nov. 6 | 9:30-10:30 a.m. | Main Event II



#### Presenter:

**Gregg L. Semenza, MD, PhD**

*Photo courtesy of Johns Hopkins*

Gregg L. Semenza is a professor of genetic medicine, pediatrics, radiation oncology and molecular radiation sciences, biological chemistry, medicine and oncology at the Johns Hopkins University School of Medicine.

Dr. Semenza is the C. Michael Armstrong Professor and serves as the director of the vascular program at the Institute for Cell Engineering.

One of today's preeminent researchers on the molecular mechanisms of oxygen regulation, Dr. Semenza has led the field in uncovering how cells adapt to changing oxygen levels. He is best known for his groundbreaking discovery of the HIF-1 (hypoxia-inducible factor 1) protein, which controls changes in gene expression in response to changes in oxygen availability. The discovery of HIF-1 has far-reaching implications for understanding and treating conditions, such as cancer and ischemic cardiovascular disease, in which hypoxia plays an important role in disease pathogenesis.

Dr. Semenza was recognized for this groundbreaking research in 2019, when he was awarded the Nobel Prize in Physiology or Medicine with William G. Kaelin, Jr., MD, of the Dana-Farber Cancer Institute, and Peter J. Ratcliffe of Oxford University.

### Novel Technologies in Arrhythmia Therapy

Nov. 6 | 9:30-10:30 a.m. | Main Event III

This Main Event highlights novel technologies that recently have and will continue to advance implantable device therapy and arrhythmia management. The session will focus on novel advances in hybrid ablation therapies, conduction system pacing, new cardiac implantable device therapies, new ablation therapies and autonomic modulation for cardiac arrhythmias.

### Paul Dudley White International Lecture and Session: Laureate, Storytelling and Novel Perspectives for Global Cardiovascular Risk Reduction

Nov. 6 | 3:30-4:30 p.m. | Main Event II



#### Esther Duflo, MA

*Photo by Kris Krüg. Originally posted to Flickr as Esther Duflo. Pop!Tech 2009. Camden, ME*

Esther Duflo is the Abdul Latif Jameel Professor of Poverty Alleviation and Development Economics in the Department of Economics at the Massachusetts Institute of Technology and a co-founder and co-director of the Abdul Latif Jameel Poverty Action Lab (J-PAL). In her research, she seeks to understand the economic lives of the poor, with the aim to help design and evaluate social policies. She has worked on health, education, financial inclusion, environment and governance.

### Long-Term Consequences of Pulmonary Embolism From Post-pe Syndrome to Chronic Thromboembolic Pulmonary Hypertension

Nov. 6 | 3:30-4:30 p.m. | Main Event III

This session focuses on the emerging data of the long-term consequences of pulmonary embolism, including evidence-based management of an array of post-thrombotic complications.

### The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary

Nov. 7 | 9:30-10:30 a.m. | Main Event I

Heart failure (HF) remains a leading cause of cardiovascular morbidity and mortality globally. In the U.S., HF is the leading cause of hospitalization among adults over age 65. There has been an explosion of novel evidence-based drug therapy for HFrEF, HFmrEF and HFpEF, with recommendations that have now been synthesized into the updated 2022 HF clinical practice guidelines.



# Presidential Session

Sunday, Nov. 6 | 1:30-3 p.m.

## Main Event I

Join us for the Presidential address featuring an inspiring Lewis A. Conner Lecture by AHA President Michelle A. Albert, MD, MPH, FAHA, an update from AHA CEO Nancy Brown and presentation of the Chairman's Award by AHA Chair Raymond P. Vara, Jr., as well as presentation of the following awards: Eugene Braunwald Award, Research Achievement Award, Basic Research Prize, Clinical Research Prize, Population Research Prize, Distinguished Scientist Recognition, Joseph A. Vita Award, Dr. Nanette K. Wenger Research Goes Red® Award and a special in memoriam tribute.

## Watch AHA tv, your source for Science News and Scientific Sessions highlights.

Check the **#AHA22** home page for bonus video and streaming content throughout the meeting.





# Late-Breaking Science

From lab to bedside, these cutting-edge abstracts unearth findings that will ultimately improve diagnosis, care and treatment and will drive heart health improvements across the spectrum.

## LBS.01. The Main Event: Changing Clinical Practice

Saturday, Nov. 5 | 9:30-10:30 a.m.

### Main Event I

- Comparative Effectiveness of Torsemide Versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial (*TRANSFORM-HF*)
- Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients With Hypertension (*DCP*)
- A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease (*PROMINENT*)

## LBS.02. Breakthrough Strategies in the HF Journey

Saturday, Nov. 5 | 3-4 p.m.

### Main Event I

- First-in-Human *in vivo* CRISPR/Cas9 Editing of the *TTR* Gene by NTLA-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- A Patient Risk-Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (*COACH*) Trial (*COACH Trial*)
- Early Results of the Patient-Reported Outcome Measurement in Heart Failure Clinic (*PRO-HF*) Trial (*PRO-HF*)
- *IRONMAN*: A Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure With Reduced Ejection Fraction (*IRONMAN*)



## Visit the Posters

Be sure to view the thousands of posters at Scientific Sessions 2022, including Moderated Digital Posters and ePosters presented each day. Posters are located in the Science & Technology Hall.

### LBS.03. High Impact Trials in Intervention and Surgery

Sunday, Nov. 6 | 8-9 a.m.

#### Main Event I

- Radial Artery Patency and Clinical Outcomes (RAPCO) Randomized Trials—The 15-Year Clinical Outcomes Comparing Radial Artery With Right Internal Thoracic Artery or With Saphenous Vein Grafting (RAPCO)
- Steroids to Reduce Systemic Inflammation After Infant Heart Surgery: The Stress Trial (STRESS Trial)
- The Impact of Chinese Herbal Medicine, Tongxinluo in Patients With Acute Myocardial Infarction—Results From the CTS-AMI Trial (CTS-AMI)
- Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Primary Results From the Multicenter, Randomized ECMO-CS Trial (ECMO-CS)

### LBS.04. Mindful Disruption of Chronic HTN Management

Sunday, Nov. 6 | 3:30-4:30 p.m.

#### Main Event I

- Effectiveness of a Village Doctor-Led Multifaceted Implementation Strategy on Cardiovascular Disease Among Patients With Hypertension: A Cluster Randomized Trial (CRHCP)
- Reducing Inequities in Care of Hypertension: Lifestyle Improvement for Everyone: Blood Pressure and Patient-Reported Outcomes (The Rich Life Project)
- The Effect of Adapted Mindfulness Training in Participants With Elevated Office Blood Pressure: The Mindfulness-Based Blood Pressure Reduction (MB-BP) Randomized Clinical Trial (The MB-BP Study)
- Efficacy and Safety of a Quadruple Ultra-Low-Dose Treatment for Hypertension (QUARTET USA): A Randomized Controlled Trial (QUARTET USA)

### LBS.05. Changing How We Prevent Cardiovascular and Renal Disease

Sunday, Nov. 6 | 5-6 p.m.

#### Main Event I

- Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy—Statin and Eicosapentaenoic Acid (RESPECT-EPA)

- Reduction of Lipoprotein(a) With Small Interfering RNA: The Results of the Ocean(a)-DOSE Trial (OCEAN(a) DOSE)
- Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial (EMPA-KIDNEY)
- Effect of Low-Dose Statin Compared With Placebo and Six Dietary Supplements on Lipid and Inflammatory Biomarkers: The SPORT Randomized Clinical Trial (SPORT)

### LBS.06. Drugs and Strategies in ACS and Revascularization

Sunday, Nov. 6 | 5-6 p.m.

#### Main Event II

- Bivalirudin With a Post-PCI High-Dose Infusion Versus Heparin Monotherapy During Primary PCI in STEMI: The Randomized Bright-4 Trial (BRIGHT-4)
- Efficacy and Safety of Indobufen Versus Aspirin After Coronary Drug-Eluting Stent Implantation: A Randomized, Open-Label, Non-Inferiority Trial (OPTION)
- Comparison of a Precision Care Strategy With Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease: The Precise Randomized Trial (PRECISE)
- ISCHEMIA-EXTENDED Follow-Up Interim Report (ISCHEMIA-EXTEND)



**Puppy Snuggles are back by popular demand!**

Visit Puppy Snuggles in Booth 2257 to put a smile on your face – and perhaps even reduce your stress.

Sponsored by  
**AMGEN**<sup>®</sup>



## Late-Breaking Science

### LBS.07. Preventing Limb Loss Through Vascular Interventions and Venous Therapies

Monday, Nov. 7 | 8-9 a.m.

#### Main Event I

- Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Clinical Results (*BEST-CLI*)
- Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Quality of Life Analyses (*BEST-CLI*)
- Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With COVID-19: Primary Results of the PREVENT-HD Randomized Clinical Trial (*PREVENT-HD*)
- A Multicenter Clustered Randomized Trial of a Universal Electronic Health Record-Based Venous Thromboembolism Risk Assessment Model as Integrated Clinical Decision Support for Prevention of Thromboembolism in Hospitalized Medically Ill Patients (*IMPROVE Trial*)

### LBS.08. Treating Atrial and Supraventricular Arrhythmias

Monday, Nov. 7 | 11 a.m.-Noon

#### Main Event I

- The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression: The Progressive-AF Trial (*PROGRESSIVE-AF*)
- Self-Administered Etipamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis From the Rapid Study (*RAPID*)
- Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients: Results From the Phase 2 NOVA Study (*NOVA*)
- Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway (*ENHANCE-AF*)

### LBS.09. Resistant HTN: A Pressure Cooker

Monday, Nov. 7 | 3-4 p.m.

#### Main Event I

- Top-Line Results of The First-in-Class Aminopeptidase-A Inhibitor Firibastat in Treatment-Resistant Hypertension (*FRESH*) Study (*FRESH*)
- Sustained Blood Pressure Lowering Effect With the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results From a Randomized, Controlled Study Including a Withdrawal Phase (*PRECISION*)
- Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients With Treatment-Resistant Hypertension (*BrigHTN*)
- Effect of Radio-Frequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results From the SPYRAL HTN-ON Med Expansion Randomized Trial (*SPYRAL HTN-ON*)

## Meet the Trialist



These small-group chats bring together perspectives from across the research community, enabling real-time discussions of challenges and potential solutions about the Late-Breaking Science being presented at Scientific Sessions.







# Featured Science

Excellence in the number of submitted abstracts this year exceeded all past records. These select Featured Sessions offer more perspectives of impressive cardiovascular science that will no doubt impact our evolving science and shape future heart health studies for years to come.

## FS.01. In-Depth and Fresh Look in Heart Failure Trials

Sunday, Nov. 6 | 8-9 a.m.

Room N230B

- The Effect of Percutaneous Revascularization on Arrhythmic Risk in Ischemic Left Ventricular Dysfunction (*REVIVED-BCIS2*)
- Natriuretic Response With Acetazolamide in Acute Heart Failure With Volume Overload: Analysis From the ADVOR Trial (*ADVOR*)
- Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Pre-Specified Analysis From the ADVOR Trial
- Empagliflozin and Cardiac Remodeling in People Without Diabetes: Primary Results of EMPA-HEART 2 CardioLink-7 Randomized Placebo-Controlled Trial (*EMPA-HEART 2*)
- First and Repeat Episodes of Worsening Heart Failure in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction: An Analysis of Deliver (*DELIVER*)

## FS.02. New Insights – Cardiac Surgery

Sunday, Nov. 6 | 9:30-10:30 a.m.

Room S103BC

- Myosin Inhibition in Patients With Obstructive HCM Referred for Septal Reduction Therapy: 32-Week Active Blinded Crossover Results From VALOR-HCM Trial (*VALOR-HCM*)
- Electrocardiographic Changes After Cardiac Surgery and 30-Day Mortality (*VISION Cardiac Surgery*)
- Interim Results of a Phase 2 Study With RBT-1 Evaluating Postoperative Course in Patients Undergoing Elective CABG/Valve Surgery on Cardiopulmonary Bypass (*The START Study*)
- Results From the Clinical Implementation of Partial Oral Treatment of Patients With Infectious Endocarditis; A Nationwide Study. Time for Poetry?



## Take a break in the new AHA Game Yard

Make sure you pencil in some fun! Challenge your friends and colleagues to a game of corn hole, ladder golf, giant tic-tac-toe and more at the AHA Game Yard in the Science & Technology Hall.

# Featured Science



Complimentary wireless internet is available during #AHA22.

## To connect:

- 1 Click on the wireless connection icon.
- 2 Select the Wi-Fi network "#AHA22."
- 3 Click "CONNECT."

Sponsored by



## FS.03. Featured Science in Heart Rhythm Medicine

Sunday, Nov. 6 | 5-6 p.m.

### Main Event III

- Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation: DASH AF Study (*DASH-AF*)
- Subcutaneous Implantable Cardioverter-Defibrillator System Post Approval Study: Primary Results (*S-ICD PAS*)
- Apixaban or Vitamin K Antagonists for Stroke Prevention in Patients With Atrial Fibrillation on Hemodialysis: Results of the Randomized Axadia-AFNET 8 Trial (*AXADIA-AFNET 8*)
- Association of Genetic Risk and Outcomes in Patients With Early Rhythm Control Therapy in Atrial Fibrillation: Results From the East-afnet4 Study (*EAST-AFNET4*)

## FS.04. Emerging Heart Failure Science

Monday, Nov. 7 | 8-9 a.m.

### Main Event II

- Safety and Efficacy of Non-Ischemic Hypothermic Machine Perfusion (*NIHP*) in Human Heart Transplantation With an Ischemic Time of 6-8 Hours
- A Randomized, Multicenter, Placebo-Controlled Trial of the Beta3 Adrenergic Agonist, Mirabegron on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease, the Beta3lvh Trial (*BETA3LVH*)
- The PreLieve Trial: Final 1-Year Outcomes of the Prospective Atrial Flow Regulator Study in Heart Failure Patients and Responder Analysis (*PreLieve*)
- Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The Breast Cancer Exercise Intervention (*BREXIT*) Study (*BREXIT*)
- Dissemination of a Decision Support Tool for Left Ventricular Assist Device: How a Majority of United States Programs Implemented I-DECIDE-LVAD into Standard Patient Evaluations (*I-DECIDE-LVAD*)
- STRONG-HF: Successful Post-Discharge Management of Heart Failure (*STRONG-HF*)

## FS.05. Evolving Science in COVID-19

Monday, Nov. 7 | 8-9 a.m.

### Main Event III

- Anti-C5a Vilobelimab Reduces All-Cause Mortality in Critically Ill COVID-19 Patients and in Those With Comorbid Hypertension: A Phase 3 Randomized Double-Blind, Placebo-Controlled Study (*PANAMO*)
- A Randomized Trial of Lipid Metabolism Modulation With Fenofibrate for Acute Coronavirus Disease 2019 (*FERMIN*)
- Impact of Coronavirus Disease-2019 on Participants in Deliver (*DELIVER*)
- Rare Coding Variants in Cardiomyopathy-Associated Genes Predispose to Severe COVID-19 and Cardiac Injury (*COVID-CARDOGEN*)
- Prevalence of Myocarditis Among Patients Hospitalized With Laboratory-Confirmed SARS-CoV-2 Infection—14 U.S. States, March 2020-May 2022 (*COVID-NET*)

## FS.06. Optimal Management Post PCI/ACS

Monday, Nov. 7 | 9:30-10:30 a.m.

### Main Event III

- Long-Term Outcomes of an Invasive Versus Conservative Strategy in Stabilized Patients Aged 80 Years or Older With Non-ST-Elevation Acute Coronary Syndrome, After Eighty Study: A Randomized Controlled Trial (*After Eighty Study*)
- Long Term Follow-Up of Aspirin Versus Clopidogrel Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: The Host-Exam Extended Study
- Impact of Ticagrelor With or Without Aspirin on Total and Recurrent Bleeding and Ischemic Events After PCI: Results From the Twilight - Recurrent Events Sub-Study (*TWILIGHT*)
- Effect of Semaglutide on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: Final Results of the Stop Study (*STOP*)

MAKING

DIFFERENCE  
INVESTMENT IMPACT



American Heart Association

Funded more than \$5 billion in research since 1949.

## FS.07. A Second Look at Practice- Changing Heart Failure Trials

Monday, Nov. 7 | 11 a.m.–Noon

### Main Event II

- The Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Results From the DELIVER Trial (*DELIVER*)
- Baseline Characteristics, Outcomes and Treatment Response to Dapagliflozin in Patients Treated With an MRA or ARNI in DELIVER (*DELIVER*)
- Sex Differences in Characteristics, Outcomes and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure (*DAPA-HF, DELIVER*)
- Differences in Clinical Characteristics, Outcomes and Treatment Response to Dapagliflozin Across the Range of Ejection Fraction in Black and White Patients With Heart Failure: A Pooled Analysis of DAPA-HF and DELIVER (*DAPA-HF, DELIVER*)
- Comparison of Clinical Outcomes and Efficacy of Empagliflozin in Black Versus White Patients With Heart Failure: A Pooled Analysis From the EMPEROR Program (*EMPEROR-Pooled*)
- Long Term Survival After Cardiac Resynchronization in Ambulatory Heart Failure (*RAFT*)

## FS.08. Digital Innovations to Improve CVD Prevention

Monday, Nov. 7 | 11 a.m.–Noon

### Main Event III

- Randomized, Controlled Trial of Digital Nutritional Cognitive Behavioral Therapy in Patients With Type 2 Diabetes Mellitus: Primary Outcomes of the BT-001 Pivotal Trial at 180 Days (*BT001 PIVOTAL*)
- A Randomized Controlled Trial of a Remotely Delivered Mobile Health Intervention to Augment Cardiac Rehabilitation: The Virtual Application-Supported ENvironment To INcrease Exercise (*VALENTINE*) Study (*The VALENTINE Study*)
- Smartphone-Based Cardiovascular Risk Reduction in Breast Cancer Patients [Smart-Breast]: A Randomized Controlled Trial (*SMART-BREAST*)

MAKING <sup>A</sup>

DIFFERENCE

INVESTMENT IMPACT



**Social Impact Fund secured \$15.1 million of grants & investments to improve the health of communities.**

- A PRagmatic Trial Of Messaging to Providers About Treatment of HyperLIPIDemia (*PROMPT-LIPID*)
- Incidental Coronary Artery Calcium: Opportunistic Screening of Prior Non-Gated Chest Cts to Improve Statin Rates (*NOTIFY-1*)

## FS.09. The Present and Future of Lipid Lowering

Monday, Nov. 7 | 3-4 p.m.

### Main Event III

- ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum Angiopoietin-Like Protein 3, Triglycerides and Cholesterol in Patients With Mixed Dyslipidemia (*ARCHES-2*)
- ARO-APOC3, an Investigational RNAi Therapeutic, Decreases Serum Apolipoprotein C3, Triglyceride, and Non-HDL-C Concentrations While Increasing HDL-C in Patients With Severe Hypertriglyceridemia (*SHASTA-2*)
- Long-Term Efficacy of Very Low LDL-Cholesterol Levels With the PCSK9 Inhibitor Evolocumab: Analysis of the FOURIER and FOURIER-OLE Studies (*FOURIER-OLE*)
- Efficacy and Safety of Twice-Yearly Subcutaneous Inclisiran in Patients With High Cardiovascular Risk and Elevated Low-Density Lipoprotein Cholesterol up to 4 Years-The Orion-3 Trial
- Individual Participant Data Meta-Analysis of New-Onset and Worsening Diabetes Mellitus in Large-Scale Randomized Double-Blind Trials of Statin Therapy



**Sneakers  
Day**

**Monday,  
Nov. 7**

Remember  
to wear your  
sneakers!

Find The **Sessions That Matter To You** With Our

# Programming Communities

Sessions are organized by programming communities in Basic Science, Clinical Science and Population Science to help you navigate the meeting.



## Basic Science

- Arteriosclerosis, Thrombosis, Vascular Biology
- Cardiac Development, Structure and Function
- Cellular Biology
- Drug Discovery
- Genetics and Genomics
- Metabolism and Physiology
- Signaling



## Clinical Science

- Acute Coronary Syndromes
- Cardio-Oncology
- Congenital Heart Disease and Pediatric Cardiology
- Electrophysiology and Arrhythmias
- Heart Failure and Cardiomyopathies
- Hypertension
- Imaging and Nuclear Medicine
- Interventional Treatments
- Nephrology
- Nursing Research and Clinical
- Pulmonary Hypertension and Critical Care
- Stroke and Neuroscience
- Surgery and Anesthesia
- Vascular Disease and Thrombosis



## Population Science

- Cardiometabolic Health and Diabetes
- Epidemiology, Big Data and Precision Medicine
- GRFW and Underrepresented Populations
- Health Tech
- Lifestyle and Behavioral Medicine
- Prevention Health & Wellness
- Quality of Care and Outcomes Research



# Livestream and OnDemand

**Livestream** 25+ hours of late-breaking science and keynote lectures featuring the most talked about new cardiovascular and brain health clinical, population and scientific updates.

You can:

- Access 260+ on-demand sessions available within 24 hours after concluding on-site in Chicago.
- Access the latest cutting-edge research from around the world with 3,000+ e-posters.
- Discover the cutting-edge science and technology advancing cardiovascular treatment in our virtual exhibit hall.
- Build relationships and share knowledge via video and text chat with the global scientific community.
- Enjoy complimentary access to all session recordings for seven days post-conference without CE credit.
- Access additional post-conference CE accreditation opportunities with the Sessions 2022 OnDemand Gold Package registration upgrade.

Experience Scientific Sessions 2022 content anytime, anywhere with **Sessions OnDemand**.

Access all the education, data and expert perspectives from the meeting — whenever and wherever you choose.

Features include:

- Access to over 300 sessions covering 27 different specialty areas
- International expert faculty and moderators
- Early Career professional development content
- Meet the Expert sessions with key thought leaders. New!
- CE credit opportunities
- Easy to use search, filter and credit claiming functionality
- Access to content Nov. 15, 2022, through Oct. 31, 2023

**To add Gold Package, visit registration on-site for assistance or visit [sessionsondemand.org](https://sessionsondemand.org) for more information.**



The Gold Package adds Sessions OnDemand to your conference registration. Extend your experience beyond the conference with access to 300+ sessions anytime, anywhere, and earn CE. Access begins on Nov. 15.

# Pre-Sessions Symposia & Early Career Day



**FRIDAY,  
NOV. 4**

**41 sessions  
over 9 hours**

Programming features distinguished symposia events, early career development offerings and more opportunities for networking and mentoring.

(Pre-Sessions Symposia & Early Career Day programming on Nov. 4 requires an extra registration fee.)

## Friday Programming

# Early Career Programming

Early career development is an exciting time as you select your specialty and visualize your next steps. Early career members engage with senior investigators who offer guidance for scientific outreach and career building. More than 30 hours of Early Career programming addresses scientific writing, conducting research, avoiding burnout and more.

**The American Heart Association and the Cardiovascular Landscape: Developing the Cardiovascular Leader in You**

Nov. 4 | 8 a.m. | Room 103BC

**Highlighting the Achievements of Our ATVB Young Members**

Nov. 4 | 9:15 a.m. | Room S103D

**Overcoming Career Challenges Due to COVID-19**

Nov. 4 | 9:15 a.m. | Room S102D

**More Training: Are You Kidding Me?**

Nov. 4 | 9:15 a.m. | Room S103BC

**Forging Your Path—Building Careers in Cardio-Oncology**

Nov. 4 | 9:15 a.m. | Room S102BC

**Early Career EP**

Nov. 4 | 9:15 a.m. | Room S102A

**Introduction to Single-Cell and Spatial Omics**

Nov. 4 | 9:15 a.m. | Room S101B

**Challenges and Solutions for Women and Underrepresented Persons Working in Hypertension Science**

Nov. 4 | 9:15 a.m. | Room S106B

**Multimodality Imaging in Chest Pain: What, When and to Which Patients**

Nov. 4 | 9:15 a.m. | Room S101A

**Kathleen A. Dracup Mentoring Award Lecture and Fireside Chat With Legends in Nursing**

Nov. 4 | 9:15 a.m. | Room S104A

**3CPR Speed Mentoring**

Nov. 4 | 9:15 a.m. | Room S104B

**Weaving Antiracism and Equity Into the Fabric of Cardiovascular Fellowship Training**

Nov. 4 | 9:15 a.m. | Room S105D

**Team Science as an Early Career Investigator: Teamwork Makes the Dream Work**

Nov. 4 | 9:15 a.m. | Room S106A

**Career Transitions: Success Stories From Two Academic Families**

Nov. 4 | 10:30 a.m. | Room S103D

**Young Hearts Mentor and Mentee Panel Discussion: Cultivating a Symbiotic Relationship**

Nov. 4 | 10:30 a.m. | Room S104B



Thank you to Pfizer for supporting the 2022  
**Lunch With Legends**

Please see registration for more information.

**Challenges and Opportunities for Recruitment and Retention for Studies Involving Participant Enrollment**

Nov. 4 | 10:30 a.m. | Room S106A

**Developing a Career in Cardio-Obstetrics: Training Opportunity and Career Growth**

Nov. 4 | 10:30 a.m. | Room S103BC

**Special Topics in Fellow to Faculty Transition in Clinical Cardiology**

Nov. 4 | 10:30 a.m. | Room S102D

**CVRI Boot Camp (Pre-Registration Required)**

Nov. 4 | 10:30 a.m. | Room S103A

**Advancing Health Equity and Inclusion in Lifestyle and Cardiometabolic Health Research**

Nov. 4 | 10:30 a.m. | Room S105D

**Cardio-Nephrology as a Career Path: What Does It Take?**

Nov. 4 | 10:30 a.m. | Room S104A

**Digital Health Equity—Leveraging Informatics Interventions to Close the Gap in Health Outcomes for Patients with Cardiac Conditions**

Nov. 4 | 10:30 a.m. | Room S106B

**3CPR Shark Tank Session**

Nov. 4 | 10:30 a.m. | Room S101B

**Early Career CVSA—Pitfalls and Pearls**

Nov. 4 | 10:30 a.m. | Room S102A

**Utilizing Registries to Investigate Vascular Disease**

Nov. 4 | 10:30 a.m. | Room S101A



**Early Career & FIT Lounge Programming**

Nov. 5-7 | Heart Hub, Science Technology Hall

This is home base and a targeted education opportunity for early career physicians, research scientists, nurses, allied health professionals and senior-level physicians and research scientists.

**Blank Page to Center Stage: Inside Tips From Physician Scientists and Journal Editors**

Nov. 5 | 9:30 a.m.

**Acceleration From FIT to Early Career: How Can Mentors Help?**

Nov. 5 | 11 a.m.

**Global Cardiovascular Diseases: Collaborative Training and Research Opportunities**

Nov. 5 | 3 p.m.

**Leveraging the Leader in Us**

Nov. 6 | 9:30 a.m.

**Finding Your Research Niche and Use What's Available**

Nov. 6 | 3:30 p.m.

**Finding Ikigai - How to Fight Burn Out During Fellowship**

Nov. 7 | 9:30 a.m.

**Creating an Equitable Future in Cardiovascular Medicine**

Nov. 7 | 11 a.m.

**Matching Into Cardiology Fellowship: The Inside Scoop From Program Directors and AHA FITs**

Nov. 7 | 12:30 p.m.

Early Career & Fit Lounge supported by





## Frontiers In Science

Pushing the boundaries of science and asking the tough questions to spark inquiry and drive advances. These sessions showcase cutting-edge research in basic, translational and clinical science focusing on cardiac arrhythmias, atherosclerosis, thrombosis and vascular disease.

**Atherosclerosis, Thrombosis and Vascular Biology: Blood Clots in Infections—Were We Ready for COVID-19?**

Nov. 4 | 2 p.m. | Room S104A

**Arrhythmia Research Summit Bench to Bedside: Translating New Players in Arrhythmogenesis**

Nov. 4 | 2 p.m. | Room S102A

**Arrhythmia Research Summit—Inherited Arrhythmias: A 2022 Update**

Nov. 4 | 2 p.m. | Room S102D

**Vascular Disease—Unmet Needs in Post-Thrombotic Syndrome: Spotlight on Mechanisms, Outcomes and Therapies**

Nov. 4 | 2 p.m. | Room S101A

**Atherosclerosis, Thrombosis and Vascular Biology: The Battle of the Lipoproteins: What Is Driving Residual Cardiovascular Risk**

Nov. 4 | 3:15 p.m. | Room S104A

**Arrhythmia Research Summit—Evaluation and Management of Syncope and Cardiac Dysautonomias: A 2022 Update**

Nov. 4 | 3:15 p.m. | Room 102D

**Arrhythmia Research Summit Bench to Bedside: Translating New Approaches to AF Ablation**

Nov. 4 | 3:15 p.m. | Room S102A

**Vascular Disease—Bringing Novel Devices to Patients**

Nov. 4 | 3:15 p.m. | Room S101A

**Arrhythmia Research Summit—Advances in Digital Health and Artificial Intelligence in Arrhythmia Management**

Nov. 4 | 4:30 p.m. | Room S102D

**Arrhythmia Research Summit—Novel Imaging Modalities From Bench to Bedside**

Nov. 4 | 4:30 p.m. | Room S102A

## State-of-the-Art Cardiovascular Care

This half-day seminar explores recent guideline-based recommendations and clinical updates to incorporate in your everyday practice.

**Primary Prevention of Cardiovascular Disease and Updates on COVID-19**

Nov. 4 | 2 p.m. | Room S103D

**Atrial Fibrillation, Stroke and Heart Failure**

Nov. 4 | 3:15 p.m. | Room S103D

**Updates in Interventional Structural Heart Disease**

Nov. 4 | 4:30 p.m. | Room S103D





## Congenital Heart Research & Innovation

You have to know where you came from in order to advance. This symposium digs into the latest findings from the CHD clinical trials and multicenter studies, dissects the successes and challenges of the past 10 years and lays out the path for future innovation.

### 2022 and Beyond: Power in Numbers: Updates on CHD Clinical Trials and Multicenter Studies

Nov. 4 | 2 p.m. | Room S103BC

### 2022 and Beyond: What Have We Learned: Successes and Challenges Over the Past Decade of CHD Clinical Research

Nov. 4 | 3:15 p.m. | Room S103BC

### 2022 and Beyond: Where Do We Go Next? Fostering Innovation & Discovery in CHD Beyond 2022

Nov. 4 | 4:30 p.m. | Room S103BC

## Heart / Kidney Symposium

The connection between kidney and heart health is undeniable. Dive into the science of cardiorenal syndrome, mechanical/circulatory therapies, a new proposed subspecialty and concerns of equity and access of new therapies including SGLT-2 inhibitors and non-steroidal MRAs.

### Heart and Kidney Outcomes Trials: A Deep Dive Into Trial Design

Nov. 4 | 2 p.m. | Room S106B

### Periprocedural Kidney Function Optimization: A Converging Point for Nephrology and Interventional Cardiology

Nov. 4 | 3:15 p.m. | Room S106B

### CRRT in the Cardiac Critical Care Setting: An Overview for the Cardiologist

Nov. 4 | 4:30 p.m. | Room S106B



**MAKING A DIFFERENCE**  
INVESTMENT IMPACT



American  
Heart  
Association

More than 2,600 HOSPITALS enrolled in  
American Heart Association Get With The Guidelines

# Special Focus Programming

## Health Equity

Ensuring every person has the opportunity to attain their full health potential and no one is disadvantaged because of social position or other socially determined circumstances is a tall but equitable order. #AHA22 offers an expansive lineup of sessions that provides a detailed roadmap for achieving it locally and globally.

**Challenges and Solutions for Women and Underrepresented Persons Working in Hypertension Science**  
Nov. 4 | 9:15 a.m. | Room S106B

**Weaving Antiracism and Equity Into the Fabric of Cardiovascular Fellowship Training**  
Nov. 4 | 9:15 a.m. | Room S105D

**Advancing Health Equity and Inclusion in Lifestyle and Cardiometabolic Health Research**  
Nov. 4 | 10:30 a.m. | Room S105D

**Digital Health Equity—Leveraging Informatics Interventions to Close the Gap in Health Outcomes for Patients With Cardiac Conditions**  
Nov. 4 | 10:30 a.m. | Room S106B

**Virtual Session: Working Toward Global Equity in Cardiovascular Care**  
Nov. 5 | 8 a.m. | Virtual Only

**Improving Diversity in the Congenital Heart Disease Workforce**  
Nov. 5 | 9:30 a.m. | Room N228

**Mechanical Complications After Acute Myocardial Infarction: What Do You Need to Know in 2022?**  
Nov. 5 | 11 a.m. | Room S103D

**Global Innovations to Transform the Medical Workforce: Addressing Unmet Cardiovascular and Other Health Needs**  
Nov. 5 | 11 a.m. | Main Event I

**Disparities in Multifactorial Cardiovascular Risk Reduction in Diabetes: Know Diabetes by Heart and Beyond**  
Nov. 5 | 11 a.m. | Room N229

**Inter- and Intragenerational Transmission of Cardiovascular Disease Risk: Does Family Matter?**  
Nov. 5 | 4:30 p.m. | Room N229

**Confronting the Epidemic of Amputations in Underserved Diabetic Populations**  
Nov. 5 | 4:30 p.m. | Room N427BC

**Implementing Machine Learning for Precision Care: Crossing the Bridge to Reality**  
Nov. 6 | 8 a.m. | Main Event III

**Health Disparities Across the Heart Failure Disease Spectrum: A Way Forward?**  
Nov. 6 | 8 a.m. | Room S105D

## Racial Disparities in Cardiovascular and Kidney Disease

Nov. 6 | 8 a.m. | Room 101B

## Bridging the Chasm: Gender, Racial and Socioeconomic Imbalances in Cardiovascular Disease

Nov. 6 | 8 a.m. | Room 102D

## Pediatric Obesity, the Next Frontier in Determinants of Health

Nov. 6 | 4:30 p.m. | Room N228

## Hypertension Across the Lifespan in Women

Nov. 6 | 9:30 a.m. | Room S101A

## Atrial Fibrillation as a Social Disease: Implications for Primary and Secondary Prevention

Nov. 6 | 9:30 a.m. | Room N230B

## The “Epidemic of Epidemics”—Intersectionality of Cardiometabolic Diseases and Social Inequalities From a Syndemic Perspective

Nov. 6 | 3:30 p.m. | Room N229

## Living Your Best Life: Targeting Equity in Palliative Care

Nov. 6 | 3:30 p.m. | Room S102D

## Are Social Determinants Permanent Going Beyond Observation to Intervention?

Nov. 6 | 3:30 p.m. | Room S104B

## Doubly Disadvantaged: Considerations for Cardiovascular Care Among Older Adults Across Gender and Racial Groups

Nov. 6 | 5 p.m. | Room N140

## Achieving Equity in Diagnosis and Treatment of Cardiac Amyloidosis and Hypertrophic Cardiomyopathy

Nov. 7 | 8 a.m. | Room N140

## Cardiovascular Disease in Diverse Immigrant Populations

Nov. 7 | 9:30 a.m. | Room N140

**MAKING A DIFFERENCE**  
INVESTMENT IMPACT



American Heart Association You're the Cure has more than 667,000 U.S. advocates for laws that protect and improve the health of all Americans.

## Claiming CE credits for #AHA22

#AHA22 attendees can receive up to 24 Continuing Education credits. CE credit claiming is limited to participation during the event Nov. 4-7, 2022. Complete the credit claim process within 30 days to avoid credit expirations.

### 1 Log in

- Go to [learn.heart.org](https://learn.heart.org)
- Click Activities in Progress
- Enter your username and password and Sign In.

### 2 Select the activity

- Select the Scientific Sessions 2022 activity
- Review the Activity Overview, scroll to the bottom and click Continue.
- View the contents of the Activity Material page and click Continue (Pharmacists will select the specific sessions attended, click Register Selected Sessions and click Continue.)

### 3 Claim credit

- Complete the conference evaluation, which is required to claim credit. Once complete, click Submit and Continue
- Click the Claim button for the appropriate accreditation.
- Click Continue to generate your certificate.
- Click Finish. The activity is stored under Transcript.



## Special Focus Programming

### Precision Medicine

Genetics, environment and lifestyle all play a role in an individual's health. Now science is flipping the equation and employing personalized medicine to better treat each individual for maximum effectiveness.

#### Introduction to Single-Cell and Spatial Omics

Nov. 4 | 9:15 a.m. | Room S101B

#### Trained Immunity and Inflammation in Atherosclerosis

Nov. 5 | 9:30 a.m. | Room S103A

#### Novel Aspects of Lipoprotein Composition and Function

Nov. 5 | 9:30 a.m. | Room S104A

#### Identifying and Practicing Emerging Genomic-Based Therapies on Cardiovascular Disease

Nov. 5 | 4:30 p.m. | Main Event III

#### Bridging Cardiology and Immunology

Nov. 6 | 9:30 a.m. | Room S104A

#### Exerkines: Mediators of Health and Disease

Nov. 6 | 9:30 a.m. | Room S106B

#### Vascular Smooth Muscle Cell Phenotypic Modulation in Vascular Disease and Aging

Nov. 6 | 5 p.m. | Room S103A

#### Advancement in Cardiovascular Single-Cell and Clonal Hematopoietic Biology

Nov. 6 | 5 p.m. | Room S104A

#### COVID-19 and the Pediatric Heart

Nov. 6 | 5 p.m. | Room N228

#### Targeting Non-Coding RNAs for Cardiovascular Therapeutics

Nov. 7 | 8 a.m. | Room S103A

#### Developmental Pathways That Impact Cardiac Disease

Nov. 7 | 8 a.m. | Room S102A

#### Novel Omics-Derived Insights Into the Pathogenesis of Pulmonary Arterial Hypertension

Nov. 7 | 8 a.m. | Room N230A

#### Health Technology Used to Effectively and Efficiently Run Real-World Efficacy Studies and Analysis

Nov. 7 | 9:30 a.m. | Room S104B

#### Clinical Debates in Cardiovascular Genetics

Nov. 7 | 11 a.m. | Room N229

#### Precision Health in Cardiovascular Nursing Science: Prevention and Management of Cardiometabolic Health in Marginalized Populations

Nov. 7 | 11 a.m. | Room S102D



## The Council Challenge: Who will dethrone CLCD?

Join us for a fierce competition in which every attendee will be a live competitor! Represent your Scientific Council, answer questions, rack up points and help your council earn global bragging rights to be called AHA's Top Council!

11:30 a.m.-12:30 p.m. | Nov. 6 | Heart Theater I



## Special Focus Programming

# Women in Science & Medicine

Women in Science & Medicine offer issue-oriented mini-sessions and support on the issues of the day.

*These sessions take place in the Go Red Women in Science & Medicine Lounge in the Heart Hub, which is located in the Science & Technology Hall.*

### Equity in Academic Research and Medicine

Nov. 5 | 9:30 a.m.

### Being a Scientist in the Social Media Age - BlackInCardio

Nov. 5 | 11 a.m.

### Microaggressions and Implicit Bias

Nov. 5 | 3 p.m.

### From Ideas on a Page to Center Stage: Secrets to Success in CV Research - CLCD WIC

Nov. 5 | 3 p.m.

### Our Stories: How Volunteering With the AHA Advanced My Career

Nov. 6 | 9:30 a.m.

### Scientific Statements 101: The Nuts & Bolts of How to Prepare, Participate and Publish an AHA Scientific Statement

Nov. 6 | 9:30 a.m.

### What to Ask for Your Startup

Nov. 6 | 3:30 p.m.



### Perspectives From Women in Vascular Specialties

Nov. 6 | 3:30 p.m.

### Resiliency: The Art and Science of Overcoming

Nov. 7 | 9:30 a.m.

### Building Successful Collaborations/ Teams

Nov. 7 | 11 a.m.

### Around the World With Go Red for Women

Nov. 7 | 12:30 p.m.



Women in Science & Medicine Lounge supported by



# Innovative Sessions you don't



## Learning Studios

Learning Studios provide a unique opportunity for companies in the field of cardiology to share their latest advances in cardiovascular practices, services and technologies.



See the *Mobile Meeting Guide App* for more details.

### Saturday, Nov. 5

TIME	LOCATION	SUPPORTER	TITLE
9:30-10:15 a.m.	Learning Studio I	Bristol-Myers Squibb	Cardiac Myosin Inhibition, and its Role in the Landscape of Symptomatic NYHA Class II-III Obstructive HCM
11-11:45 a.m.	Learning Studio I	CSL Behring, LLC	Conversations in Cholesterol Efflux: How Can We Harness its Cardioprotective Potential?
	Learning Studio II	Boehringer Ingelheim Corporation	Jardiance® (empagliflozin) Tablets: A Review of the Latest Data
12:30-1:15 p.m.	Learning Studio I	Amgen, Inc.	Help Your MI Patients Achieve Lower LDL-C and Reduce the Risk of Another MI
	Learning Studio II	Janssen Pharmaceuticals, Inc.	Expert Perspectives on the Management of Patients With CAD and/or PAD
1:45-2:30 p.m.	Learning Studio I	Novartis Pharmaceuticals Corporation	Rethinking the Approach: Management of Elevated LDL-C in Patients With ASCVD
	Learning Studio II	Bayer HealthCare Pharmaceuticals Inc.	Getting to the Heart of the Matter: Management of CV Risk in Patients With CKD Associated With T2D
3-3:45 p.m.	Learning Studio I	Pfizer Inc.	Hiding in Plain Sight: Identification and Management of ATTR-CM Patients
	Learning Studio II	Elucid Biomed, Inc.	Solving the Heart Attack Crisis With Next Generation Plaque Analysis

### Sunday, Nov. 6

TIME	LOCATION	SUPPORTER	TITLE
9:30-10:15 a.m.	Learning Studio II	Cytokinetics, Inc.	Is the Burden of Symptomatic Chronic HFREF Inevitable? Defining and Recognizing Early Signs or Symptoms of WHF
11-11:45 a.m.	Learning Studio I	Novartis Pharmaceuticals Corporation	How Can Twice-Yearly* LEQVIO Help Certain ASCVD Patients Who Are Overburdened by the Daily Demands of their Treatment Plan? *After 2 Initial Doses
	Learning Studio II	Sanofi	Changing Views on Rhythm Control: Is Earlier Better for Improving Outcomes in AF Patients?
12:15-1 p.m.	Learning Studio I	Amgen, Inc.	Targeting LDL-C in ASCVD Patients: Are We There Yet?
	Learning Studio II	Merck	Treatment Considerations for Patients with HFREF and Select Updates From the 2022 HF Guideline
3:30-4:15 p.m.	Learning Studio I	American Heart Association & National Hispanic Latino Cardiovascular Collaborative (NHLCC)	Fostering the Future of Hispanic Health
	Learning Studio II	American Heart Association Lifelong Learning	The Role of Antiarrhythmic Drugs in Early Rhythm Control and the Management of Atrial Fibrillation

### Monday, Nov. 7

TIME	LOCATION	SUPPORTER	TITLE
9:30-10:15 a.m.	Learning Studio I	Kiniksa Pharmaceuticals	Treating Recurrent Pericarditis and Preventing Recurrence

# want to miss



## Roundtables

Join in on small-group, topic-driven discussions to flesh out ideas and science with colleagues.

### Saturday, Nov. 5

TIME	LOCATION	SUPPORTER	TITLE
9:30-10 a.m.	Heart Theater II	HCM Roundtable	HCM: Understanding the Patient Journey
11-11:30 a.m.	Heart Theater II	Medtronic	Latest Hypertension Consensus Publications
12:30-1 p.m.	Heart Theater II	Impulse Dynamics	CCM Therapy: Your Patients Want to Feel Better

### Sunday, Nov. 6

TIME	LOCATION	SUPPORTER	TITLE
11-11:30 a.m.	Heart Theater II	Impulse Dynamics	Operationalizing CCM® Therapy
3:30-5 p.m.	Heart Theater II	NHLBI Showcase	NHLBI Company Showcase



## Visit the Science & Technology Hall

### South Hall, Level 3

Discover the cutting-edge science and technologies that are advancing cardiovascular treatment by visiting our industry supporters.

### Hours

#### Saturday, Nov. 5

9 a.m.-4:30 p.m.

#### Sunday, Nov. 6

9 a.m.-5 p.m.

#### Monday, Nov. 7

9 a.m.-3 p.m.



**MAKING A DIFFERENCE**  
INVESTMENT IMPACT



16 million patients benefiting from organizations participating in Target: BP™

Largest voluntary organization dedicated to fighting heart disease & stroke



American Heart Association.

# VISIT HeartQuarters AT SESSIONS

## Saturday, Nov. 5

**SCIENCE & TECHNOLOGY HALL HOURS:**  
9 a.m.-4:30 p.m.

**HALL BREAKS:**  
9-9:30 a.m.  
10:30-11 a.m.  
12-3 p.m.  
4-4:30 p.m.

## Sunday, Nov. 6

**SCIENCE & TECHNOLOGY HALL HOURS:**  
9 a.m.-5 p.m.

**HALL BREAKS:**  
9-9:30 a.m.  
10:30 a.m.-1:30 p.m.  
3-3:30 p.m.  
4:30-5 p.m. CST

## Monday, Nov. 7

**SCIENCE & TECHNOLOGY HALL HOURS:**  
9 a.m.-3 p.m.

**HALL BREAKS:**  
9-9:30 a.m.  
10:30-11 a.m.  
12-3 p.m.



Please check the Mobile Meeting Guide App for programming in the HeartQuarters theater.

## Wear Red Day SUNDAY, NOV. 6

American Heart Association.



Remember to **wear red on Sunday** and Go Red For Women®. Show your support and connect with colleagues and patients nationwide who share your commitment to prevent heart disease and stroke.

## Learn more about AHA Professional Membership

Members lead with heart, share their science with the world, join others with the same calling, engage at meetings that matter, lead in their community, plus so much more.

As a member in one of our 16 scientific councils, you can engage in and advocate for your science interests as part of a global network of key science thought leaders.

Through your work on development of guidelines and statements, peer review, planning science programming, mentoring or as an expert spokesperson you will build lifelong connections and engage in career-developing initiatives.

**Visit the Professional Membership booth in HeartQuarters to learn how you can get more involved with the American Heart Association.**



# Explore new opportunities with AHA



LOCATED  
IN THE  
HEART HUB

## EmPOWERED to Serve™

Join the movement to drive change in local communities by eliminating health disparities through the improvement of social determinants of health.

## Scientific Journals

Visit HeartQuarters to pick up free copies of our scientific journals and article highlights. Get the quick reference “AHA Journals’ Overview & Publishing Guide” and learn how to submit a manuscript. Access the revamped edition of “AHA Journals’ Trend Watch” featuring more than 60 free, full-text articles.

[ahajournals.org](http://ahajournals.org).

## Quality Improvement

Visit the theater to learn how American Heart Association–supported implementation science projects have helped improve care and processes for rural health, pain management and treatment of heart failure, diabetes, ASCVD, aortic stenosis and atrial fibrillation at institutions around the world. Get inspired by brief, power-packed presentations to accelerate your own process improvement plan.

## Healthcare Certification

Learn how your facility can earn the Heart-Check mark, a symbol of your commitment to providing quality care in your community.

## Get With The Guidelines®

Participants will model share how their institutions have changed or improved as part of their participation in the quality program. Cast your vote to determine showcase winners! Don't forget to visit the Genius Bar, where quality improvement teams will demonstrate and discuss Get With The Guidelines registries, including dashboards, bundled reporting and more.

## Research & Precision Medicine Platform

Learn how to use Get With The Guidelines and COVID-19 CVD datasets for your own research using this machine learning research tool.

## Research Funding & Peer Review

Learn about AHA research awards and opportunities to evaluate proposals.

## Rural Health Care Outcomes Accelerator

Learn how AHA is working to overcome disparities in rural health care by supporting rural hospitals with no-cost access to add new Get With The Guidelines programs, education, and collaboration opportunities.

[www.heart.org/ruralaccelerator](http://www.heart.org/ruralaccelerator)

## Mission: Lifeline®

Learn more about our national, community-based initiative improving systems of care for patients with ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), stroke and out-of-hospital cardiac arrest.

## Lifelong Learning

Find on-demand educational activities, professional resources and more. Learn about the types of continuing education credit available and why we are the premier provider of education for health care professionals.

## Professional Heart Daily

See the latest cardiovascular news during Scientific Sessions.

## Patient Education Programs

Learn how our health tools and resources can help you provide effective care and disease management strategies to your patients. Stop by our booth today!

## Know Diabetes By Heart™

Learn more about Know Diabetes By Heart™ which is a joint initiative of American Heart Association and the American Diabetes Association's which aims to help people living with type 2 diabetes lower their risk for cardiovascular disease, stroke and kidney disease by connecting them and the health professionals who care for them with education and resources.

## AHA International

AHA is actively working in over 100 countries with 200 cardiovascular societies and organizations around the world to educate and inform, help change policies, implement programs, and strengthen healthcare systems to help improve and save lives. Discover more about our global work in resuscitation education, healthcare quality improvement, advocacy and science advancement.

## Five resources to empower your patients

# 1

### The American Stroke Association

Each year about 1 in 3 Ischemic Strokes are classified as cryptogenic (undetermined cause). The ASA's Secondary Stroke Prevention Initiative is aimed at encouraging collaboration with neurologists, cardiologists, electrophysiologists, and other health care team members to dig deeper for a definitive diagnosis and potential stroke risk factors. Access free recurrent stroke prevention resources at [stroke.org/cryptogenic](http://stroke.org/cryptogenic).

# 2

### CPR & Emergency Cardiovascular Care: Inspiring the World to Save Lives

As the authority in resuscitation science, research and training, we publish the official AHA Guidelines for CPR and ECC, and translate these guidelines into the highest quality training materials.

# 3

### Healthy for Good™

Healthy for Good is a movement designed to inspire people to adopt healthy practices through a simple science-based approach: Eat smart. Move more. Be well. Join the movement today at [healthyforgood.heart.org](http://healthyforgood.heart.org).

# 4

### Patient Education

Pick up the latest information and resources for patients and consumers:

- AFib Awareness
- Getting to the Heart of Stroke™
- Heart Insight magazine
- HeartCare™ Channel
- Heart Failure
- High Blood Pressure
- Know Diabetes By Heart™
- No Surprises Act patient education
- Peripheral Artery Disease
- Stroke
- Target: Aortic Stenosis

# 5

### Support Network

Encourage your patients and their family members to join AHA's Support Network at [www.heart.org/supportnetwork](http://www.heart.org/supportnetwork) to connect with others like them, share experiences and access informational resources that support their health journeys.



American Heart Association.

Scientific Sessions



TCT


An Educational Collaboration

## New alliance offers enhanced lineup at #AHA22

As part of a new educational collaboration between the American Heart Association's Scientific Sessions and the Cardiovascular Research Foundation's TCT Conference, #AHA22 will feature an exciting lineup of TCT at AHA programming to advance the latest research in cardiovascular disease and interventional therapies.

*Download the Mobile Meeting Guide App to view the latest on these exciting sessions.*

*Scan the QR code below for your device to download the Mobile Meeting Guide App.*



### TCT at Scientific Sessions 2022 programming

#### **Interventional Theater: Case Presentation and Discussion Revascularization Guidelines to Practice**

Saturday, Nov. 5 | 11 a.m.-12:30 p.m.

Case Theater

Science and Technology Hall, Level 3

#### **Structural Case Theater - State-of-the-Art Cases in Structural Interventions**

Saturday, Nov. 5 | 1 p.m.-2:30 p.m.

Case Theater

Science and Technology Hall, Level 3

#### **What's New in the Management of Uncontrolled/Resistant Hypertension**

Sunday, Nov. 6 | 9:30 a.m.-10:30 a.m.

Case Theater

Science and Technology Hall, Level 3

#### **State-of-the-Art Updates on the Management of CLTI**

Sunday, Nov. 6 | 11:30 a.m.-1 p.m.

Case Theater

Science and Technology Hall, Level 3

#### **Predicting the Future of MedTech: Transformative Concepts and Technological Trends**

Sunday, Nov. 6 | 9:30 a.m.-10:30 a.m.

Health Innovation Pavilion

Heart Hub, Science and Technology Hall, Level 3

#### **Late-Breaking Science: Drugs and Strategies in ACS and Revascularization**

Sunday, Nov. 6 | 5-6 p.m.


Main Event II

**Paid Advertisement**

Following hospitalization for HF or outpatient IV diuretic use in adults with symptomatic chronic HF and ejection fraction less than 45%

**Provide a stabilizing force when your patient needs it most.**

 **Verquvo**<sup>®</sup>  
(vericiguat) tablets  
2.5 mg, 5 mg, 10 mg



Not an actual patient.

HF = heart failure; IV = intravenous.

## **Indications and Usage**

VERQUVO is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

## **SELECTED SAFETY INFORMATION**


### **WARNING: EMBRYO-FETAL TOXICITY**

**Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.**

Please read the adjacent Brief Summary of the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

# VERQUVO was studied in high-risk patients following a worsening HF event, who were at higher risk for future events<sup>1</sup>

Patients enrolled in the VICTORIA study had recently experienced worsening HF events despite being well-treated



Primary composite endpoint of CV death and HFH: Event rate (% of patients per year)<sup>a</sup>

**37.8%** Of patients per year in the placebo arm of the VICTORIA study, who were on guideline-recommended therapies, experienced an HF hospitalization or CV death

- Among these patients, guideline-recommended therapies included beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), combination of an angiotensin receptor and neprilysin inhibitor (ARNIs), or sodium glucose co-transporter 2 (SGLT2) inhibitors

## Study Design

VICTORIA was a Phase 3, randomized, parallel-group, placebo-controlled, double-blind, event-driven, multicenter trial comparing VERQUVO to placebo when added to background HF therapy in 5,050 adult patients with NYHA class II-IV chronic HF and LVEF <45% following a worsening HF event (defined as HF hospitalization within 6 months before randomization or use of outpatient IV diuretics for HF within 3 months before randomization). Patients were treated up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo. The primary endpoint was a composite of time to first event of CV death or HF hospitalization.<sup>2</sup>

<sup>a</sup>Total patients with an event per 100 patient years at risk.

CV = cardiovascular; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; VICTORIA = Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.

## SELECTED SAFETY INFORMATION

- VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.
- VERQUVO is contraindicated in pregnancy.
- **Embryo-Fetal Toxicity:** Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.

Please read the adjacent Brief Summary of the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

 **Verquvo**<sup>®</sup>  
(vericiguat) tablets  
2.5 mg, 5 mg, 10 mg

# Help keep patients moving forward following a worsening HF event

Once-daily VERQUVO provided a powerful annualized absolute risk reduction of CV death or HF hospitalization compared to placebo

Primary composite endpoint of CV death or HF hospitalization in the VICTORIA study<sup>a</sup>

**4.2%**  annualized **ARR<sup>b</sup>**

**NNT of 24**

HR=0.90 (95% CI: 0.82-0.98)  $P=0.019^{c,d}$

For 1 year to prevent 1 event

Based on an event rate of **33.6%** of patients per year for VERQUVO (N=2,526) vs **37.8%** of patients per year for placebo (N=2,524)<sup>e</sup>

Primary endpoint results show a risk reduction in both CV death and HF hospitalization with VERQUVO compared to placebo

VERQUVO demonstrated a tolerability profile that was similar to placebo

**16%**  
VERQUVO  
(N=2,519)

HYPOTENSION

**15%**  
Placebo  
(N=2,515)

**10%**  
VERQUVO  
(N=2,519)

ANEMIA

**7%**  
Placebo  
(N=2,515)

<sup>a</sup>For patients with multiple events, only the first event contributing to the composite endpoint is counted.

<sup>b</sup>ARR, calculated as the difference (placebo - VERQUVO) in event rate per 100 patient years.

<sup>c</sup>HR (VERQUVO over placebo) and CI from a Cox proportional hazards model.

<sup>d</sup>From the log-rank test.

<sup>e</sup>Total patients with an event per 100 patient years at risk.

ARR = absolute risk reduction; CI = confidence interval; HR = hazard ratio; N = number of patients in intent-to-treat (ITT) population for efficacy outcomes<sup>2</sup>; N = all patients as treated for safety analyses<sup>2</sup>; NNT = number needed to treat.

## SELECTED SAFETY INFORMATION

- In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency  $\geq 5\%$ , were hypotension (16% vs 15%) and anemia (10% vs 7%).
- Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.
- There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.

Please read the adjacent Brief Summary of the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

 **Verquvo<sup>®</sup>**  
(vericiguat) tablets  
2.5 mg, 5 mg, 10 mg

Following HF hospitalization or outpatient IV diuretic use in adults with symptomatic chronic HF and ejection fraction less than 45%

# VERQUVO could be the stabilizing force they need to move forward

VERQUVO may help reduce the risk of HF hospitalization or CV death for the high-risk HFrEF patient<sup>1</sup>



VERQUVO delivered a **4.2% annualized ARR** compared to placebo<sup>a</sup> based on an event rate of **33.6% of patients per year for VERQUVO (N=2,526)** and **37.8% of patients per year for placebo (N=2,524)<sup>b</sup>**



**Annualized NNT of 24**

For 1 year to prevent 1 event



**Convenient once-daily dosing**

The recommended starting dose of VERQUVO is 2.5 mg orally once daily with food. Double the dose of VERQUVO approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablets, VERQUVO may be crushed and mixed with water immediately before administration.

Visit [verquvohcp.com](http://verquvohcp.com) for more information

<sup>a</sup>ARR, calculated as difference (placebo - VERQUVO) in event rate per 100 patient years.

<sup>b</sup>Total patients with an event per 100 patient years at risk.

Click [here](#) for study description.

HFrEF = heart failure with reduced ejection fraction.

## Indications and Usage

VERQUVO is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

## SELECTED SAFETY INFORMATION

- VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.
- VERQUVO is contraindicated in pregnancy.
- **Embryo-Fetal Toxicity:** Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.

**Please read the adjacent Brief Summary of the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.**

**References:** **1.** Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. *J Am Coll Cardiol.* 2019;73(8):935-944. **2.** Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med.* 2020;382(20):1883-1893.



Copyright © 2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. US-VER-01290 09/21

 **Verquvo**<sup>®</sup>  
(vericiguat) tablets  
2.5 mg, 5 mg, 10 mg

## Brief Summary of the Prescribing Information for VERQUVO® (vericiguat) tablets: 2.5 mg, 5 mg, 10 mg

### WARNING: EMBRYO-FETAL TOXICITY

**Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.**

### INDICATIONS AND USAGE

VERQUVO® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

### DOSE AND ADMINISTRATION

#### Recommended Dosage

The recommended starting dose of VERQUVO is 2.5 mg orally once daily with food.

Double the dose of VERQUVO approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.

For patients who are unable to swallow whole tablets, VERQUVO may be crushed and mixed with water immediately before administration.

#### Pregnancy Testing in Females of Reproductive Potential

Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with VERQUVO.

### CONTRAINDICATIONS

VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.

VERQUVO is contraindicated in pregnancy.

### WARNINGS AND PRECAUTIONS

#### Embryo-Fetal Toxicity

Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.

#### ADVERSE REACTIONS

##### Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

VERQUVO was evaluated in VICTORIA, which included 2,519 patients treated with VERQUVO (up to 10 mg once daily). The mean duration of VERQUVO exposure was 1 year, and the maximum duration was 2.6 years. Table 1 lists adverse drug reactions occurring more commonly with VERQUVO than placebo and in ≥5% of patients treated with VERQUVO in VICTORIA.

Table 1: Adverse Drug Reactions Occurring with VERQUVO in VICTORIA

Adverse Drug Reaction	VERQUVO % N = 2,519	Placebo % N = 2,515
Hypotension	16	15
Anemia	10	7

### DRUG INTERACTIONS

#### Other Soluble Guanylate Cyclase Stimulators

VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.

#### PDE-5 Inhibitors

Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended because of the potential for hypotension.

### USE IN SPECIFIC POPULATIONS

#### Pregnancy

##### Risk Summary

Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy. There are no available data with VERQUVO use in pregnant women. In animal reproduction studies, oral administration of vericiguat to pregnant rabbits during organogenesis, at ≥4 times the human exposure (total AUC) with the maximum recommended human dose (MRHD) of 10 mg, resulted in malformations of the heart and major vessels, as well as increased number of abortions and resorptions. In a pre/postnatal toxicity study, vericiguat administered orally to rats during gestation through lactation caused maternal toxicity, which resulted in decreased pup body weight gain (≥10 times the MRHD) and increased pup mortality (24 times the MRHD) during the preweaning period.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

If a patient becomes pregnant while receiving VERQUVO, healthcare providers should report VERQUVO exposure by calling 1-877-888-4231.

#### Data

##### Animal Data

In an embryo-fetal development study in rabbits, vericiguat was administered orally to pregnant rabbits during the period of organogenesis from gestation day (GD) 6 to 20 at doses of 0.75, 2.5 or 7.5 mg/kg/day.

An increased incidence of cardiac ventricular septal defect along with truncus arteriosus communis was observed at ≥2.5 mg/kg/day, which is ≥4 times the human exposure at the MRHD. Maternal toxicity (decreased food consumption and body weight loss), which may have resulted in late spontaneous abortions and resorptions was noted at ≥2.5 mg/kg/day (≥4 times the human exposure at the MRHD). There were no maternal toxicity or abortions/resorptions and no malformations of the heart and major vessels in rabbits at an exposure approximately equivalent to the human exposure at the MRHD.

In a prenatal developmental toxicity study in rats, vericiguat was administered orally to pregnant rats during the period of organogenesis from GD 6 to 17 at doses of 5, 15 or 50 mg/kg/day. No developmental toxicity was observed up to the highest dose (36 times the human exposure [total AUC] at the MRHD). Maternal toxicity (decreased body weight gain and food consumption) was observed at ≥15 mg/kg/day (≥10 times the human exposure at the MRHD). There was no maternal toxicity at 5 mg/kg/day (4 times the human exposure at the MRHD).

In a pre-postnatal development study in rats, vericiguat was administered orally at doses of 7.5, 15 or 30 mg/kg/day from GD 6 through lactation day 21. Maternal toxicity (decreases in food consumption and body weight gain) was observed at all dose levels ≥6 times the human exposure (total AUC) at the MRHD and resulted in decreased pup body weight gain at ≥15 mg/kg/day (≥10 times the human exposure at the MRHD) and pup mortality at 30 mg/kg/day (24 times the MRHD).

[<sup>14</sup>C]-vericiguat was administered orally to pregnant rats at a dose of 3 mg/kg. Vericiguat-related material was transferred across the placenta, with fetal plasma concentrations of approximately 67% maternal concentrations on GD 19.

#### Lactation

##### Risk Summary

There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or the effects on milk production. Vericiguat is present in the milk of lactating rats and it is likely that vericiguat or its metabolites are present in human milk. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.

#### Data

[<sup>14</sup>C]-vericiguat was administered intravenously to lactating rats at a dose of 1 mg/kg. Vericiguat-related material was excreted into milk at concentrations approximately 12% maternal plasma concentrations on LD 8.

### Females and Males of Reproductive Potential

#### Pregnancy Testing

Verify the pregnancy status in females of reproductive potential prior to initiating VERQUVO.

#### Contraception

##### Females

VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment and for one month after the final dose.

#### Pediatric Use

Safety and effectiveness of VERQUVO have not been established in pediatric patients.

#### Geriatric Use

No dosage adjustment of VERQUVO is required in geriatric patients. In VICTORIA, a total of 1,596 (63%) patients treated with VERQUVO were 65 years and older, and 783 (31%) patients treated with VERQUVO were 75 years and older. No overall differences in safety or efficacy of VERQUVO were observed between patients aged 65 years and older compared to younger patients, but greater sensitivity of some older individuals cannot be ruled out.

#### Renal Impairment

No dosage adjustment of VERQUVO is recommended in patients with estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73m<sup>2</sup> who are not on dialysis. VERQUVO has not been studied in patients with eGFR <15 mL/min/1.73m<sup>2</sup> at treatment initiation or on dialysis.

#### Hepatic Impairment

No dosage adjustment of VERQUVO is recommended in patients with mild or moderate hepatic impairment (e.g., Child-Pugh A or B). VERQUVO has not been studied in patients with severe hepatic impairment (e.g., Child-Pugh C).

### OVERDOSAGE

Limited data are available with regard to overdosage in human patients treated with VERQUVO. In VICTORIA, doses up to 10 mg have been studied. In a study of patients with preserved ejection fraction heart failure (left ventricular ejection fraction ≥45%), multiple doses of VERQUVO 15 mg have been studied and were generally well tolerated. In the event of an overdose, hypotension may result. Symptomatic treatment should be provided. VERQUVO is unlikely to be removed by hemodialysis because of high protein binding.

For more detailed information, please read the Prescribing Information.

uspi-mk1242-t-2106r001

Revised: 06/2021

# Discover the latest in the Science & Technology Hall

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions. Data current as of October 10, 2022.

The Science & Technology Hall serves as host to myriad learning and engagement opportunities at Scientific Sessions 2022. The Heart Hub is at the center of more than 130 exhibitors, poster presentation areas, Heart Theater, Health Tech, Learning Studios, Roundtables and more opportunities for high-impact meet-ups.

## A-C

**AHA Game Yard 2055**

**ADInstruments, Inc. 2306**

2205 Executive Circle  
Colorado Springs, CO 80906  
**e** [sales.na@adinstruments.com](mailto:sales.na@adinstruments.com)  
**w** [adinstruments.com](http://adinstruments.com)  
ADInstruments believes in making science easier. Powerful, flexible and accurate, our products are cited in more than 30,000 research papers in peer-reviewed journals and our equipment is the preferred choice for thousands of scientists.

**AltaThera Pharmaceuticals 2601**

311 S. Wacker Drive, Suite 6030  
Chicago, IL 60606  
AltaThera is a hospital-focused specialty pharmaceutical company committed to providing therapies that address the costly and complex challenges of adult atrial fibrillation.

**Amarin Pharma, Inc. 805**

440 Route 22, Suite 300  
Bridgewater, NJ 08807  
**w** [amarincorp.com](http://amarincorp.com)  
Our lead commercial product, VASCEPA®/VAZKEPA® (icosapent ethyl), creates a new paradigm in cardiovascular disease management and is positioned to address cardiovascular risk for millions of patients globally.

**AASM** American Academy of SLEEP MEDICINE™

**American Academy of Sleep Medicine 2614**

2510 N. Frontage Road  
Darien, IL 60561  
**e** [accreditation@aasm.org](mailto:accreditation@aasm.org)  
**w** [aasm.org](http://aasm.org)

AASM is the only professional society dedicated exclusively to the medical subspecialty of sleep medicine. The AASM sets standards and promotes excellence in sleep medicine health care, education, and research.

**American College of Cardiology 2224**

2400 N. St. NW  
Washington, DC 20037  
**e** [membercare@acc.org](mailto:membercare@acc.org)  
**w** [ACC.org/ACCcentral](http://ACC.org/ACCcentral)  
Over its 70-year history, the American College of Cardiology (ACC) has grown into the global leader in transforming cardiovascular care and improving heart health. ACC serves as the professional home for the entire cardiovascular care team.

**American College of Physicians/Annals of Internal Medicine 2613**

190 N. Independence Mall West  
Philadelphia, PA 19106  
**e** [annals@acponline.org](mailto:annals@acponline.org)  
**w** [acponline.org](http://acponline.org)  
American College of Physicians provides education, information and advocacy for over 160,000 internal medicine specialists and subspecialists and publishes Annals





of Internal Medicine & MKSAP19. Stop by Booth 2613 for more information.

**Amgen** 400  
One Amgen Center Drive  
Thousand Oaks, CA 91320  
**w** [amgen.com](http://amgen.com)

**Association of Black Cardiologists** 2712  
2400 N. St. NW, Suite 200  
Washington, DC 20037  
**e** [info@abc cardio.org](mailto:info@abc cardio.org)  
**w** [abc cardio.org](http://abc cardio.org)  
Founded in 1974, the Association of Black Cardiologists, Inc. is a nonprofit organization dedicated to eliminating the disparities related to cardiovascular disease, including strokes, in all people of color.

**AstraZeneca** 2213  
1800 Concord Pike  
Wilmington, DE 19803  
**e** [karen.wilthew2@astrazeneca.com](mailto:karen.wilthew2@astrazeneca.com)  
**w** [astrazeneca-us.com](http://astrazeneca-us.com)  
AstraZeneca (CVRM)  
By following the science to understand the links between the heart, kidneys and pancreas, AstraZeneca focuses on medicines to help improve outcomes, reduce risks and tackles co-morbidities.

**AstraZeneca Medical Affairs** 2602  
1800 Concord Pike  
Wilmington, DE 19720  
**w** [astrazeneca-us.com](http://astrazeneca-us.com)

**AtriCure** 2604  
7555 Innovation Way  
Mason, OH 45040  
**w** [atricure.com](http://atricure.com)  
AtriCure provides innovative technologies for the treatment of AFib. Hybrid AF Therapy is a minimally invasive, cardiac ablation that combines the expertise of cardiac surgeons and electrophysiologists.

**Bayer** 1611  
100 Bayer Blvd.  
Whippany, NJ 07981  
**w** [pharma.bayer.com](http://pharma.bayer.com)  
Bayer is a leader in cardiovascular and kidney disease, that delivers science for a better life. Visit <https://pharma.bayer.com>.

**BetterNight** 2305  
5471 Kearny Villa Road, Suite 200  
San Diego, CA 92123

**Biofourmis** 1813  
33 Arch St., Floor 18  
Boston, MA 02110  
**w** [biofourmis.com](http://biofourmis.com)  
Biofourmis is a global leader in virtual care and digital therapeutics. We offer innovative solutions that enable clinicians to deliver personalized predictive care. Biofourmis solutions are backed by artificial intelligence and machine learning.

**BMS/Pfizer** 2009  
235 East 42nd St.  
New York, NY 10017  
**w** [bmspfizercongressresources.com](http://bmspfizercongressresources.com)  
The Bristol Myers Squibb and Pfizer alliance is a worldwide collaboration bringing together two leading companies focused on cardiovascular disease with a shared vision to reduce NVAf-related stroke and treat DVT/pulmonary embolism events.

**Boehringer Ingelheim/ Lilly USA** 2800  
900 Ridgebury Road  
Ridgefield, CT 06877  
**e** [info@boehringer-ingelheim.com](mailto:info@boehringer-ingelheim.com)  
**w** [pro.boehringer-ingelheim.com/us/products/jardiance](http://pro.boehringer-ingelheim.com/us/products/jardiance)  
Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA welcome you and look forward to the opportunity to share the latest clinical information on our products. Visit <http://us.boehringer-ingelheim.com> or [lilly.com](http://lilly.com).

**Brelyon** 2702  
930 Park Place  
San Mateo, CA 94403  
**e** [info@brelyon.com](mailto:info@brelyon.com)  
**w** [www.brelyon.com](http://www.brelyon.com)  
Brelyon is an MIT spin-off pioneering a new category of large-format virtual monitors, which offers a 10' screen in a 32" form factor for medical applications like imaging/radiology, robotic surgery, laparoscopy/endoscopy, and training/simulation.

**Bristol Myers Squibb** 2000, 2806, 800  
3401 Princeton Pike  
Lawrence Township, NJ 08648  
**w** [bms.com](http://bms.com)  
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases.

**Cardiometabolic Health Congress** 608  
1801 N. Military Trail, Suite 200  
Boca Raton, FL 33431  
**e** [info@cardiometabolichealth.org](mailto:info@cardiometabolichealth.org)  
**w** [cardiometabolichealth.org](http://cardiometabolichealth.org)  
A resource for practicing clinicians, students and patients interested in cardiometabolic health, Cardiometabolic Health Congress (CMHC) offers up-to-date research, news, publications and much more in this quickly evolving field.

**Care Access** 2815  
33 Arch St., 17th Floor  
Boston, MA 02110

**Certara** 2915  
100 Overlook Center, Suite 101  
Princeton, NJ 08540  
**e** [marketing@certara.com](mailto:marketing@certara.com)  
**w** [certara.com](http://certara.com)  
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development.

**Charmcare Co. Ltd.** 2906

#714, 2, Gasan digital 1-ro  
Geumcheon-gu  
Seoul, Seoul 08591  
Republic of Korea  
**e** [info@charmcare.com](mailto:info@charmcare.com)  
**w** [charmcare.com](http://charmcare.com)

Charmcare is a medical device manufacturer. We produce pulse oximeters and blood pressure monitors, R&D, manufacturing and sales.

**CSL Behring** 1804

1020 First Ave.  
King of Prussia, PA 19406  
**w** [cslbehring.com](http://cslbehring.com)

CSL Behring is committed to developing novel therapies that save and improve the lives of patients with life-threatening diseases. As part of this commitment, we have established a Therapeutic Area that focuses on cardiovascular and metabolic disease.

**CVRx** 2803

9201 West Broadway Ave., Suite 650  
Minneapolis, MN 55445  
**w** [cvrx.com](http://cvrx.com)

CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure.

**Cytokinetics** 1604

350 Oyster Point Blvd.  
South San Francisco, CA 94080  
**e** [medicalaffairs@cytokinetics.com](mailto:medicalaffairs@cytokinetics.com)

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases.

**D-F****Daxor Corporation** 2707

107 Mecco Lane  
Oak Ridge, TN 37830  
**e** [info@daxor.com](mailto:info@daxor.com)  
**w** [daxor.com](http://daxor.com)

Daxor markets the BVA-100® diagnostic blood test to objectively quantify blood volume status and composition — improving patient outcomes, including reducing readmissions and mortality and hospital length of stay by enabling volume-guided management.

**Dexcom** 2216

6340 Sequence Drive  
San Diego, CA 92121  
**e** [events@dexcom.com](mailto:events@dexcom.com)  
**w** [dexcom.com](http://dexcom.com)

Dexcom, Inc., founded in 1999, empowers people to take control of diabetes with innovative continuous glucose monitoring (CGM) systems.

**Doximity** 1858

500 Third St., Suite 510  
San Francisco, CA 94107  
**w** [doximity.com](http://doximity.com)

Doximity is the leading digital platform for U.S. medical professionals. The company's mission is to help doctors be more productive so they can provide better care for their patients.

**Duke Clinical Research Institute** 1600

300 W. Morgan St., Suite 800  
Durham, NC 27701  
**e** [elizabeth.evans@duke.edu](mailto:elizabeth.evans@duke.edu)  
**w** [dcri.org](http://dcri.org)

The DCRI utilizes world-class practicing clinicians and operational expertise to improve the care of patients globally through clinical research. We conduct groundbreaking trials, manage major patient registries and perform cutting-edge research.

**Edwards Lifesciences** 811

One Edwards Way  
Irvine, CA 92614  
**e** [THVConferences@Edwards.com](mailto:THVConferences@Edwards.com)  
**w** [Edwards.com](http://Edwards.com)

Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring.

**Elsevier, Inc.** 709

1600 John F. Kennedy Blvd.,  
Suite 1800  
Philadelphia, PA 19103  
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, and deliver better care.


**Elucid** 2411

2 Park Plaza, 700  
Boston, MA 02215  
**p** 978-473-1986  
**w** [elucid.com](http://elucid.com)

Our mission is to provide comprehensive and accurate clinical insights, based on ground-truth histology and machine learning, enabling unprecedented precision health care for vascular disease.

**Esperion Therapeutics** 1010

450 East St.  
Doylestown, PA 18901

**FDA Center for Tobacco Products 2715**

10903 New Hampshire Ave.  
Document Control Center, Bldg 71,  
Room G335  
Silver Spring, MD 20993  
**e** [AskCTP@fda.hhs.gov](mailto:AskCTP@fda.hhs.gov)  
**w** [fda.gov/tobacco-products](http://fda.gov/tobacco-products)  
To make tobacco-related disease and death part of America's past, not America's future, and, by doing so, ensure a healthier life for every family.

**FujiFilm VisualSonics, Inc. 1810**

3080 Yonge St., Suite 6100  
Toronto, ON M4N3N1  
Canada  
**w** [visualsonics.com](http://visualsonics.com)  
FUJIFILM VisualSonics, Inc. is the undisputed world leader in high-resolution ultrasound systems designed for cardiovascular research. Our Vevo systems operate at 10-70 MHz, achieving up to 30 µm resolution.

## G-I

**HCPLive® 1912**

2 Clarke Drive, Suite 100  
Cranbury, NJ 08512  
**w** [hclive.com](http://hclive.com)  
HCPLive® is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients.

**HeartFlow 2317**

331 E. Evelyn Ave.  
Mountain View, CA 94041  
**e** [support@heartflow.com](mailto:support@heartflow.com)  
**w** [heartflow.com](http://heartflow.com)  
HeartFlow's FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this to evaluate the impact a blockage has on blood flow and

determine the best treatment for patients.

**HeartLab 2700**

238 Khyber Pass Road  
Auckland, IL 1023  
New Zealand  
**e** [conor.sutherland@heartlab.com](mailto:conor.sutherland@heartlab.com)  
**w** [heartlab.com](http://heartlab.com)  
For clinicians who want a faster, easier way to work, HeartLab builds the next generation of cardiology imaging solutions. Our services are truly cloud native and built to be fast, intuitive and adaptive to the rapidly changing clinical workflow.

**Humacyte, Inc. 2918**

2525 NC 54  
Durham, NC 27713  
**w** [humacyte.com](http://humacyte.com)  
Humacyte, Inc. is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to improve the lives of patients and transform the practice of medicine.

**Hypertrophic Cardiomyopathy Association 1913**

66 Ford Road, Suite 312B  
Denville, NJ 07834  
**w** [4hcm.org](http://4hcm.org)

**Impulse Dynamics 2227**

401 Route 73N, Building 50,  
Suite 100  
Marlton, NJ 08053  
**w** [impulsedynamics.com](http://impulsedynamics.com)

**Inari Medical 2316**

6001 Oak Canyon, Suite 100  
Irvine, CA 92618  
**e** [info@inarimedical.com](mailto:info@inarimedical.com)  
**w** [inarimedical.com](http://inarimedical.com)  
Inari Medical is pioneering therapeutic treatments for venous thromboembolism by developing thrombectomy products to extract large clot burden from big vessels

without the need for thrombolytic drugs.

**Intermountain Healthcare 2017**

5121 S. Cottonwood St.  
Murray, UT 84107  
**w** [intermountainhealthcare.org](http://intermountainhealthcare.org)  
Intermountain Healthcare is a leader in providing evidence-based, best-practice heart and vascular care to patients throughout the nation. Based in Salt Lake City, Intermountain Healthcare has 33 hospitals and 385 clinics across the Intermountain West.

**Invitae 2607**

1400 16th St.  
San Francisco, CA 94103  
**e** [clientservices@invitae.com](mailto:clientservices@invitae.com)  
**w** [invitae.com](http://invitae.com)  
Invitae's mission is to bring comprehensive genetic information into mainstream medicine to improve health care for everyone. We offer high-quality, affordable testing across all of life's stages. Visit [invitae.com](http://invitae.com).

**IonOptix 2505**

396 University Ave.  
Westwood, MA 02090  
**e** [info@ionoptix.com](mailto:info@ionoptix.com)  
**w** [ionoptix.com](http://ionoptix.com)  
IonOptix develops and manufactures data acquisition and analysis systems for cardiovascular research, principally functional characterization of excitation-contraction coupling in isolated cardiomyocytes, iPSC-cardiomyocytes and cardiac tissue.

## J-L

**JAMA Network 713**

330 N. Wabash Ave., Suite 39300  
Chicago, IL 60611  
**w** [jamanetwork.com](http://jamanetwork.com)  
JAMA Network advances the science and practice of cardiology with high-

impact journals, including *JAMA*, *JAMA Cardiology*, *JAMA Internal Medicine*, *JAMA Network Open*, and more. Visit Booth 713 for the latest articles and information about publishing in *JAMA*.

**Janssen Pharmaceutical Medical Affairs** 2809  
1125 Trenton-Harbourton Road  
Titusville, NJ 08560  
[w janssen.com](http://w.janssen.com)

**Janssen Pharmaceuticals, Inc.** 1213  
1125 Trenton-Harbourton Road  
Titusville, NJ 08560  
[w janssen.com](http://w.janssen.com)

**Janssen Scientific Affairs** 2416  
1125 Trenton-Harbourton Road  
Titusville, NJ 08560  
[w janssen.com](http://w.janssen.com)

**Kiniksa Pharmaceuticals Corp.** 1824, 1915  
100 Hayden Ave.  
Lexington, MA 02421  
[w kiniksa.com](http://w.kiniksa.com)  
Kiniksa is a global biopharmaceutical company that finds and delivers novel treatments for patients with significant unmet need. We are focused on building a better future for patients by developing a portfolio of differentiated therapies.

**Know Diabetes By Heart** 2252  
7272 Greenville Ave.  
Dallas, TX 75231  
[e michelle.bruns@heart.org](mailto:michelle.bruns@heart.org)  
[w knowdiabetesbyheart.org/professional](http://w.knowdiabetesbyheart.org/professional)  
The American Heart Association and the American Diabetes Association, along with industry leaders, are working together on the groundbreaking initiative Know Diabetes By Heart™ to reduce cardiovascular deaths, heart attacks, heart failure and stroke

**Knowledge Portal Network** 2612  
Broad Institute of MIT and Harvard  
75 Ames St.  
Cambridge, MA 02142  
[w KP4CD.org](http://w.KP4CD.org)

**Labcorp Drug Development** 1911  
206 Carnegie Center  
Princeton, NJ 08540  
[w drugdevelopment.labcorp.com](http://w.drugdevelopment.labcorp.com)  
Labcorp Drug Development is a leading clinical research organization that provides pharmaceutical and biotech clients with vital information to accelerate innovations and improve patient health through our unparalleled drug development capabilities.

**Lexicon Pharmaceuticals, Inc.** 2404  
2445 Technology Forest Blvd .  
The Woodlands, TX 77381  
[w lexpharma.com](http://w.lexpharma.com)  
Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions.

## M-O

**Mayo Clinic** 2004  
200 First St. SW, Gonda 6-472  
Rochester, MN 55905  
[e willis.niconna@mayo.edu](mailto:willis.niconna@mayo.edu)  
[w cveducation.mayo.edu](http://w.cveducation.mayo.edu)  
The Mayo Clinic Departments of Cardiovascular Medicine and Cardiovascular Surgery are on the leading edge of treating cardiovascular and cardiothoracic conditions and providing CME courses, board reviews, podcasts and a free video center.

**Med Learning Group** 2617  
9309 N. Florida Ave., Suite 100  
Tampa, FL 33612  
[w medlearninggroup.com](http://w.medlearninggroup.com)

**Medtronic** 2027  
710 Medtronic Parkway  
Minneapolis, MN 55432  
[w medtronic.com](http://w.medtronic.com)  
We lead global health care technology. Our mission — to alleviate pain, restore health and extend life. Transforming the lives of two people every second, every hour, every day. Medtronic. Engineering the extraordinary.

**Merck & Co., Inc.** 813  
2000 Galloping Hill Road  
Kenilworth, NJ 07033  
[w merck.com](http://w.merck.com)  
At Merck, we use the power of leading-edge science to save and improve lives around the world. We've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

**Metabolic Endocrine Education Foundation** 2713  
18372 Clark St., Suite 212  
Tarzana, CA 91356  
[w tmioa.com](http://w.tmioa.com)  
MEEF is a leading national health foundation devoted to improving patients & public health through education. MEEF currently sponsors educational activities focusing on heart and diabetes for professional and healthcare providers.

**MiCare Path** 2907  
5900 Poplar Ave., Suite 212  
Memphis, TN 38119  
[e monte.greer@micarepath.com](mailto:monte.greer@micarepath.com)  
[w micarepath.com](http://w.micarepath.com)  
MiCare Path is personalizing peace of mind beyond the office visit.

**Milestone Pharmaceuticals 1807**

6210 Ardrey Kell Road, Suite 650  
Charlotte, NC 28277

**w** [milestonepharma.com](http://milestonepharma.com)

We are a patient-centric, clinical-stage biopharmaceutical company dedicated to bringing an investigational medication to patients living with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation (AFib).

**Mineralys Therapeutics, Inc. 2704**

150 N.Radnor Chester Road,  
Suite F200  
Radnor, PA 19087

**e** [evonne.matthews@comcast.net](mailto:evonne.matthews@comcast.net)

**w** [mineralystx.com](http://mineralystx.com)

**Moor Instruments 2304**

501 Silverside Road, Suite 66  
Wilmington, DE 19809

**w** [moorinc.com](http://moorinc.com)

Moor Instruments specializes in advanced, high-quality tools to help assess your microvascular blood flow and oxygenation needs including traditional laser Doppler, laser speckle and non-invasive blood pressure. Stop by the booth for a free demo!

**Murata Vios 2217**

700 Commerce Drive, Suite 190  
Woodbury, MN 55125

**My Health Connection 2206**

16662 Hale Ave.  
Irvine, CA 92606

**e** [support@myhealthconnection.tv](mailto:support@myhealthconnection.tv)

My Health Connection is a telehealth company that specializes in cardiac non-invasive monitoring of hemodynamics.

**NEJM Group 714**

860 Winter St.  
Waltham, MA 02451

NEJM Group creates high-quality medical resources for research, learning, practice, and professional development designed to meet the demand for essential medical knowledge. Products include the New

England Journal of Medicine and NEJM Journal Watch.

**Nightingale Health Plc 2407**

Mannerheimintie 164a  
Helsinki, PA 00300  
Finland

**w** [research.nightingalehealth.com](http://research.nightingalehealth.com)

Next generation clinical chemistry for research. One 100ul sample, one test, 250 biomarkers. Results are applicable to all disease areas and include 39 clinically validated biomarkers. Enjoy our affordable pricing from USD 23 per sample.

**Northwestern Medicine 1817**

251 E. Superior  
Chicago, IL 60611

**e** [BCVI\\_info@nm.org](mailto:BCVI_info@nm.org)

**w** [heart.nm.org](http://heart.nm.org)

Northwestern Medicine's Bluhm Cardiovascular Institute—a health care destination for highly specialized cardiovascular care. In 2022-23, U.S. News & World Report ranked our cardiovascular program top 10 in the nation and No. 1 in Illinois for 15 years.

**Novartis Pharmaceuticals Corporation 1200**

One Health Plaza  
East Hanover, NJ 07936

**w** [novartis.com](http://novartis.com)

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need.

**Novo Nordisk, Inc. 2024,2204**

800 Scudders Mill Road  
Plainsboro, NJ 08536

**w** [novonordisk-us.com](http://novonordisk-us.com)

For more than 90 years, Novo Nordisk, a global leader in health care, has been discovering and developing innovative medicines to help people with chronic diseases lead longer, healthier lives.

**Novo Nordisk Medical 2511**

800 Scudders Mill Road  
Plainsboro, NJ 08536

**e** [EDFA@novonordisk.com](mailto:EDFA@novonordisk.com)

**w** [novonordisk.com](http://novonordisk.com)

Novo Nordisk is a leading global health care company, founded in 1923 in Denmark, dedicated to supporting advances in the treatment of cardiovascular diseases through meaningful innovation and strategic partnerships.

**OM1 2113**

31 St. James Ave., Suite 1125  
Boston, MA 02116

**w** [om1.com](http://om1.com)

OM1 offers industry-leading enriched health care datasets, research analytics, data modeling, decision support and retrospective and prospective clinical studies with a focus on the highest quality data and clinical outcomes.

**Orbikor 2307**

500 Sur de Paco Torres del Country  
Escazu, San Jose 10203  
Costa Rica

**w** [unnomed.com](http://unnomed.com)

Orbikor Technologies addresses one of the world's largest medical challenges: the management and prevention of Cardiovascular Disease. UnnoMed is an IoMT (Internet of Medical Things) platform for the connected management of cardiovascular health.

## P-R

**Pfizer Medical Affairs – Rare Cardiology 1616**

235 E. 42nd St.  
New York, NY 10017

**w** [pfizer.com](http://pfizer.com)

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

**Pharmacosmos** 2513  
Roervangsvej 30  
Holbaek, 4300  
Denmark  
Pharmacosmos Group founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency anaemia.

**Precigen Exemplar** 1812  
P.o. Box 198  
Sioux Center, IA 51250  
[w exemplargenetics.com](http://w.exemplargenetics.com)  
Precigen Exemplar is the leading provider of GE MiniSwine research models of human disease. Our models assist in the optimization and efficacy of novel therapeutics. Combined with our preclinical service capabilities we help speed time to the clinic.

**Puppy Snuggles** 2257

**QT Medical, Inc.** 2207  
1360 Valley Vista Drive, Suite 2  
Diamond Bar, CA 91765  
[w qtmedical.com](http://w.qtmedical.com)  
QT Medical is a medtech company with a focus on high-quality 12-lead diagnostic electrocardiogram (ECG) for use by health care professionals and patients.

**Rajant Health, Inc.** 2406  
200 Chesterfield Road  
Malvern, PA 19355  
[w rajant.health](http://w.rajant.health)  
Rajant Health Inc. develops cutting-edge health technology to provide health insights on-demand. Our intelligent products make raw data understandable for researchers, health care providers and everyday individuals so they can live healthier lives.

**ReCor Medical** 2014  
1049 Elwell Court  
Palo Alto, CA 94303  
[w recormedical.com](http://w.recormedical.com)  
ReCor Medical is a medical device company that designs and manufactures the Paradise Ultrasound Renal Denervation System, a proprietary ultrasound ablation system for renal denervation (uRDN).

**Regeneron Pharmaceuticals, Inc.** 2912  
777 Old Saw Mill River Road  
Tarrytown, NY 10591  
[w regeneron.com](http://w.regeneron.com)  
Regeneron is a leading biotechnology company that invents medicines for serious diseases. Visit [Regeneron.com](http://Regeneron.com) to learn more.

**Roche Diagnostics** 2507  
9115 Hague Road  
Indianapolis, IN 46256  
[w usdiagnostics.roche.com](http://w.usdiagnostics.roche.com)  
Roche leads the industry in the development of diagnostics products for cancer, cardiac health, infectious diseases, women's health and in diabetes management.

## S-U

**SANOFI** 1005  
50 Binney St.  
Cambridge, MA 02142  
[w sanofi.com](http://w.sanofi.com)

**Scarf King** 2818  
18 Meadow Lane  
Roslyn H.T.S, NY 11577

**Silence Therapeutics Plc** 2812  
72 Hammersmith Road  
London, W14 8TH  
United Kingdom  
[w silence-therapeutics.com](http://w.silence-therapeutics.com)  
Silence Therapeutics is a leader in the discovery, development and delivery of novel short interfering

ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet need.

**SomaLogic** 2114  
2945 Wilderness Place  
Boulder, CO 80301  
[e events@somalogic.com](mailto:e.events@somalogic.com)  
[w somalogic.com](http://w.somalogic.com)  
We offer SomaScan Discovery, a 7,000 target proteomic analysis tool, which is used in a range of applications from biomarker discovery to target validation, as well as a variety of uses in clinical trials.

**Tempus** 2606  
600 W. Chicago 510  
Chicago, IL 60654  
Data-driven precision medicine. Finding and helping patients with undiagnosed or under treated cardiovascular diseases.

**The Japanese Circulation Society** 710  
6th Floor, Uchikanda Central Building,  
1-18-13 Uchikanda, Chiyoda-ku  
Tokyo, AP 101-0047  
Japan  
[e international@j-circ.or.jp](mailto:e.international@j-circ.or.jp)  
[w j-circ.or.jp/english](http://w.j-circ.or.jp/english)  
Established in 1935, the Japanese Circulation Society has been promoting basic and clinical research activities and education in the scientific area of the circulatory organ system for approximately 85 years.

**The National Heart, Lung, and Blood Institute** 1814  
31 Center Drive, Building 31  
Bethesda, MD 20892  
[e NHLBIinfo@nhlbi.nih.gov](mailto:e.NHLBIinfo@nhlbi.nih.gov)  
[w nhlbi.nih.gov](http://w.nhlbi.nih.gov)  
NHLBI provides global leadership for a research, training and education program to promote the prevention and treatment of heart, lung and blood disorders and enhance the health of all individuals so that they can live longer.

**theheart.org/Medscape  
Cardiology 1209**

395 Hudson St., Third Floor  
New York, NY 10014

Medscape is the leading source of clinical news, health information, medical education and point-of-care tools for health care professionals, offering specialists and other health professionals the most robust and integrated medical information

**TIMI Study Group 2413**

350 Longwood Ave.,  
First Office Floor  
Boston, MA 02115

**e** [timi@partners.org](mailto:timi@partners.org)

**w** [timi.org](http://timi.org)

Since its inception in 1984, the principal goal of the TIMI Study Group has been to conduct high quality clinical trials that enhance the care of patients suffering from cardiovascular disease and its risk factors.

**Us2.ai 2013**

2 College Road 02-00  
Singapore, South East 169850  
Singapore

**e** [info@us2.ai](mailto:info@us2.ai)

**w** [us2.ai](http://us2.ai)

AI for fully automated analysis and reporting of echocardiograms.

## V-Z

**VectorBuilder, Inc. 2600**

1010 W. 35th St., Suite 515  
Chicago, IL 60609

**e** [outreach@vectorbuilder.com](mailto:outreach@vectorbuilder.com)

**w** [vectorbuilder.com](http://vectorbuilder.com)

VectorBuilder is a global leader in gene delivery technologies. We offer a full spectrum of gene delivery solution. VectorBuilder is a full-service CDMO with extensive experience in

cGMP vector manufacturing, and offers a number of CRO services.

**Vektor Medical, Inc. 2218**

9255 Towne Centre Drive, Suite 750  
San Diego, CA 92121

**e** [emilylovell@vektormedical.com](mailto:emilylovell@vektormedical.com)

**w** [vektormedical.com](http://vektormedical.com)

Vektor's mission is to improve outcomes in cardiology care by innovating smart, non-invasive arrhythmia mapping technologies.

**Viz.AI 2504**

548 Market St.  
San Francisco, CA 94104

**e** [hello@viz.ai](mailto:hello@viz.ai)

Viz.ai is the leading platform, leveraging artificial intelligence and machine learning to improve clinical care and accelerate treatments and technology.

**Wolters Kluwer 616**

Two Commerce Square  
2001 Market St.  
Philadelphia, PA 19103

**w** [shop.lww.com](http://shop.lww.com)

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and the next generation of health care providers.

**World Heart Federation 2615**

32 Rue Des Malatrex  
Geneva, AL 1201  
Switzerland

**w** [worldheart.org](http://worldheart.org)

A leader and convener in global cardiovascular health, the World Heart Federation champions heart health and acts to reduce the global burden of heart disease and stroke, which together claim 18.6 million lives every year.

**ZOLL Medical Corporation 2200**

269 Mill Road  
Chelmsford, MA 01824

**w** [zoll.com](http://zoll.com)

ZOLL® Medical Corporation, a leader in medical devices and software solutions, helps hospital professionals manage, treat and save lives while also increasing operational efficiency.



**VISIT THE SCIENCE  
& TECHNOLOGY HALL**  
*South Hall, Level 3*

**Saturday, Nov. 5: 9 a.m.-4:30 p.m.**

**Sunday, Nov. 6: 9 a.m.-5 p.m.**

**Monday, Nov. 7: 9 a.m.-3 p.m.**

# Exhibitors by Community



## Join the Wellness Challenge

Compete against your fellow attendees in this spirited activity.

Visit Wellness Challenge booth on Level 2.5 for more information.

Wellness Challenge sponsored by



Be sure to visit our booth 2024 to learn more and to collect additional Wellness Challenge points!

## Basic Science

### Arteriosclerosis, Thrombosis and Vascular Biology

FujiFilm VisualSonics, Inc.  
Intermountain Healthcare  
Know Diabetes By Heart  
Precigen Exemplar  
The National Heart, Lung, and Blood Institute

### Cardiac Development, Structure and Function

ADInstruments, Inc.  
FujiFilm VisualSonics, Inc.  
HeartLab  
IonOptix  
SANOFI

## Cellular Biology

IonOptix  
VectorBuilder Inc.

## Drug Discovery

Bayer  
Precigen Exemplar  
VectorBuilder Inc.

## Genetics and Genomics

Intellia TX  
Knowledge Portal Network  
Rajant Health, Inc.  
VectorBuilder, Inc.

## Metabolism and Physiology

ADInstruments, Inc.  
IonOptix  
Knowledge Portal Network

## Signaling

ADInstruments, Inc.

## Clinical Science

### Acute Coronary Syndromes

Intermountain Healthcare

### Cardio-Oncology

MiCare Path

### Congenital Heart Disease and Pediatric Cardiology

QT Medical, Inc.

### Electrophysiology and Arrhythmias

AtriCure  
Medtronic  
Milestone Pharmaceuticals  
QT Medical, Inc.  
SANOFI  
Vektor Medical, Inc.

### Heart Failure and Cardiomyopathies

Bristol Myers Squibb  
Cytokinetics  
Daxor Corporation  
Intellia TX  
Medtronic  
Merck & Co., Inc.  
Precigen Exemplar  
SANOFI  
Us2.ai





## Hypertension

ReCor Medical

## Imaging and Nuclear Medicine

FujiFilm VisualSonics, Inc.

HeartFlow

HeartLab

Us2.ai

## Interventional Treatments

Amarin Pharma, Inc.

Intermountain Healthcare

Kiniksa Pharmaceuticals Corp

Milestone Pharmaceuticals

## Nephrology

Know Diabetes By Heart

MiCare Path

## Nursing Research and Clinical

Milestone Pharmaceuticals

## Pulmonary Hypertension & Critical Care

Daxor Corporation

## Stroke and Neuroscience

Moor Instruments

## Population Science

### Cardiometabolic Health and Diabetes

Amarin Pharma, Inc.

Bayer

Know Diabetes By Heart

Knowledge Portal Network

Nightingale Health Plc

Regeneron Pharmaceuticals Inc.

### Epidemiology, Big Data & Precision Medicine

Nightingale Health Plc

OM1

The National Heart, Lung, and Blood Institute

### Go Red for Women and Underrepresented Populations

The National Heart, Lung, and Blood Institute

## Health Tech

Charmcare Co Ltd

HeartLab

MiCare Path

OM1

QT Medical, Inc.

Rajant Health, Inc.

Us2.ai

Vektor Medical, Inc.

## Prevention Health and Wellness

Amarin Pharma, Inc.

Charmcare Co Ltd

Rajant Health Inc.

## Quality of Care and Outcomes Research

Charmcare Co Ltd

Daxor Corporation

OM1

Vektor Medical, Inc.

# Take some science home

Pick up your  
complimentary  
copy of Abstracts  
on USB in the Science  
& Technology Hall,  
Booth 2404.

Sponsored by  
Lexicon Pharmaceuticals



# Product Categories

Improve your search for companies providing products and services you need by using this listing of companies by Product Categories.

## Associations

### International Societies

American College of Cardiology  
Hypertrophic Cardiomyopathy Association  
The Japanese Circulation Society  
World Heart Federation



### Professional Association

American Academy of Sleep Medicine  
American College of Cardiology  
American College of Physicians/Annals of Internal Medicine  
FDA Center for Tobacco Products  
JAMA Network  
VectorBuilder, Inc.



While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.

Data current as of October 10, 2022.



## Education

### Certification and Recertification

American College of Cardiology  
American College of Physicians/Annals of Internal Medicine  
Cardiometabolic Health Congress  
Know Diabetes By Heart  
Mayo Clinic  
Metabolic Endocrine Education Foundation

### Education, Teaching Aids, CME

Cardiometabolic Health Congress  
FDA Center for Tobacco Products  
Know Diabetes By Heart  
Mayo Clinic  
Med Learning Group  
NEJM Group  
NorthEast Monitoring, Inc.  
theheart.org/Medscape Cardiology

### Teaching Aids, CME

ADInstruments, Inc.  
American College of Cardiology

## Hospital/Institution/Practice

### Health Care Facilities Design/Construction

Mayo Clinic  
Northwestern Medicine  
Ognomy

### Recruitment

Intermountain Healthcare

## Imaging

### Angiographic Viewers and Work Stations

Elucid  
HeartLab

### CV Imaging Equipment

Elucid  
FujiFilm VisualSonics, Inc.  
HeartLab

### Echocardiography Equipment

FujiFilm VisualSonics, Inc.  
HeartLab  
Vektor Medical, Inc.

## Information Technology

### Web-Based Image Management and Reporting Solutions

HeartLab

### Electronic Health Records/Electronic Medical Records (EHR/EMR)

Medical AI, Inc.  
MiCare Path  
Ognomy

### Electronic Health Records/Electronic Medical Records (EHR/EMR)

HeartLab

### Electronic Information Services and Equipment

Medical AI, Inc.  
OM1

### Physician Practice Services and Management

Doximity

### Technology-Computer Hardware, Software and/or Patient Management Tools With Medical Applications

Biofourmis  
HeartFlow  
HeartLab  
Knowledge Portal Network  
Medical AI, Inc.  
MediWhale  
Ognomy  
SomaLogic  
Vektor Medical, Inc.  
Viz.AI

### Web-Based Image Management and Reporting Solutions

Biofourmis  
MiCare Path  
QT Medical Inc.  
Us2.ai

## Medical Equipment

### Patient Monitoring Systems

Biofourmis

## Medical Device

### Therapeutics

Biofourmis  
Humacyte, Inc.  
Impulse Dynamics  
Precigen Exemplar  
ReCor Medical

## Medical Devices

### Arrhythmia Monitoring Equipment

Medical AI, Inc.  
Vektor Medical, Inc.

### Blood Pressure Monitoring Equipment

ADInstruments, Inc.  
Charmcare Co Ltd  
Moor Instruments  
Orbicor

### Diagnostic Catheters and Devices

AtriCure  
Invitae  
Medtronic

### ECG Equipment

ADInstruments, Inc.  
QT Medical, Inc.

### ECG Equipment, Medical Devices

Medical AI, Inc.

### External Defibrillators

ZOLL Medical Corporation

### Instrumentation

Daxor Corporation  
FujiFilm VisualSonics, Inc.  
Harvard Bioscience  
IonOptix  
Moor Instruments  
Vektor Medical, Inc.

# Product Categories

## **Interventional-Coronary**

Elucid  
ZOLL Medical Corporation

## **Interventional-Other Percutaneous Endovascular and Cardiac Devices**

Elucid  
Inari Medical  
Medtronic  
ReCor Medical

## **Interventional-Peripheral**

Elucid

## **Pacing and Rhythm Management Devices**

CVRx  
Medtronic

## **Prostheses, Valves and Pumps**

Edwards Lifesciences

## **Telemedicine**

Biofourmis  
Ognomy  
QT Medical, Inc.

## **Medical Equipment**

### **Clinical Laboratory and Testing Services**

Invitae  
Nightingale Health Plc

### **Exercise Testing**

ADInstruments, Inc.

### **Noninvasive Monitoring and Testing**

ADInstruments, Inc.  
DWL USA  
FujiFilm VisualSonics, Inc.  
Invitae  
Moor Instruments  
Murata Vios  
Vektor Medical, Inc.

### **Patient Monitoring Systems**

MiCare Path  
Roche Diagnostics

### **Supplies**

Invitae

## **Pharmaceuticals**

### **Diagnostics Medications**

Biofourmis

## **Therapeutic Medications**

AltaThera Pharmaceuticals  
Amarin Pharma, Inc.  
Amgen  
Bayer  
Boehringer Ingelheim/Lilly USA  
Bristol Myers Squibb  
CSL Behring  
Cytokinetics  
Intellia TX  
Janssen Pharmaceutical Medical Affairs  
Janssen Pharmaceuticals, Inc.  
Janssen Scientific Affairs  
Kiniksa Pharmaceuticals Corp  
Lexicon Pharmaceuticals, Inc.  
Merck & Co., Inc.  
Milestone Pharmaceuticals  
Mineralys Therapeutics, Inc.  
Novartis Pharmaceuticals Corporation  
Novo Nordisk, Inc.  
Novo Nordisk Medical  
Pharmacosmos  
Regeneron Pharmaceuticals Inc.  
SANOFI  
Silence Therapeutics Plc

## **Publications, Books and Journals**

American College of Physicians/  
Annals of Internal Medicine  
Elsevier, Inc.  
FDA Center for Tobacco Products  
HCPLive®  
JAMA Network  
NEJM Group  
Wolters Kluwer

## **Research**

### **Clinical Trials**

Association of Black Cardiologists  
Biofourmis  
Duke Clinical Research Institute  
NEJM Group  
Northwestern Medicine  
The National Heart, Lung, and Blood Institute  
TIMI Study Group

### **Market Research**

Certara  
OM1

### **Statistical Research Tools**

Certara  
OM1  
Rajant Health, Inc.

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.

Data current as of October 10, 2022.

# Exhibitors by Booth

400	Amgen	1913	Hypertrophic Cardiomyopathy Association
608	Cardiometabolic Health Congress	1915	Kiniksa Pharmaceuticals Medical
616	Wolters Kluwer	1958	MediWhale
709	Elsevier, Inc.	2000	Bristol Myers Squibb
710	The Japanese Circulation Society	2004	Mayo Clinic
713	JAMA Network	2009	BMS/Pfizer
714	NEJM Group	2013	Us2.ai
800	Bristol Myers Squibb	2014	ReCor Medical
805	Amarin Pharma, Inc.	2017	Intermountain Healthcare
811	Edwards Lifesciences	2024	Novo Nordisk Inc
813	Merck & Co., Inc.	2027	Medtronic
1005	SANOFI	2055	Activity Zone
1010	Esperion Therapeutics	2113	OM1
1200	Novartis Pharmaceuticals Corporation	2114	SomaLogic
1209	theheart.org/ Medscape Cardiology	2200	ZOLL Medical Corporation
1213	Janssen Pharmaceuticals, Inc.	2204	Novo Nordisk Inc
1600	Duke Clinical Research Institute	2206	My Health Connection
1604	Cytokinetics	2207	QT Medical Inc.
1611	Bayer	2213	AstraZeneca
1616	Pfizer Medical Affairs – Rare Cardiology	2216	Dexcom
1804	CSL Behring	2217	Murata Vios
1807	Milestone Pharmaceuticals	2218	Vektor Medical, Inc.
1810	FujiFilm VisualSonics, Inc.	2224	American College of Cardiology
1812	Precigen Exemplar	2227	Impulse Dynamics
1813	Biofourmis	2252	Know Diabetes By Heart
1814	The National Heart, Lung, and Blood Institute	2257	Puppy Snuggles
1817	Northwestern Medicine	2304	Moor Instruments
1824	Kiniksa Pharmaceuticals Corp	2305	BetterNight
1858	Doximity	2306	ADInstruments, Inc
1910	NorthEast Monitoring, Inc.	2307	Orbicor
1911	Labcorp Drug Development	2316	Inari Medical
1912	HCPLive®	2317	HeartFlow
		2404	Lexicon Pharmaceuticals, Inc.
		2406	Rajant Health Inc.
		2407	Nightingale Health Plc
		2411	Elucid
		2413	TIMI Study Group



2416	Janssen Scientific Affairs	2712	Association of Black Cardiologists
2504	Viz.AI	2713	Metabolic Endocrine Education Foundation
2505	IonOptix	2715	FDA
2507	Roche Diagnostics	2718	FDA Center for Tobacco Products
2511	Novo Nordisk Medical	2800	Boehringer Ingelheim/ Lilly USA
2513	Pharmacosmos	2803	CVRx
2600	VectorBuilder Inc.	2806	Bristol Myers Squibb
2601	AltaThera Pharmaceuticals	2809	Janssen Pharmaceutical Medical Affairs
2602	AstraZeneca Medical Affairs	2812	Silence Therapeutics Plc
2604	AtriCure	2815	Care Access
2606	Tempus	2818	Scarf King
2607	Invitae	2906	Charmcare Co Ltd
2612	Knowledge Portal Network	2907	MiCare Path
2613	American College of Physicians/Annals of Internal Medicine	2912	Regeneron Pharmaceuticals Inc.
2614	AASA	2915	Certara
2616	American Academy of Sleep Medicine	2918	Humacyte, Inc.
2617	Med learning		
2618	World Heart Federation		
2700	HeartLab		
2702	Breylon		
2704	Mineralys Therapeutics, Inc		
2707	Daxor Corporation		



# Posters

Four zones group the posters by subject matter plus a fifth zone dedicated to Best of Specialty Conferences posters.

Rapid-Fire Forums, located in each poster area, draw attendees in for original science presentations and interactions with abstract authors.

Check the mobile meeting app for the schedule of the moderated digital posters.

Scan the QR code below for your device to download the Mobile Meeting Guide App.




Download on the App Store

GET IT ON Google Play



For all other devices Web Version

Google Play and the Google Play logo are trademarks of Google LLC. Apple and the Apple logo are registered trademarks of Apple Inc.



# Science & Technology Hall

South Hall, Third Floor

Saturday, Nov. 5  
9 a.m.-4:30 p.m.

Sunday, Nov. 6  
9 a.m.-5 p.m.

Monday, Nov. 7  
9 a.m.-3 p.m.



# Heart Hub

The Heart Hub is a unique learning and networking destination where attendees can participate in a variety of immersive, interactive and educational opportunities all in one place.

The Heart Hub includes:

- Learning Studios
- Health Innovation Pavilion
- Early Career & FIT Lounge
- Women in Science & Medicine Lounge
- FAHA Lounge
- Braindate Lounge
- Recharge/Headshot Lounge
- Get With The Guidelines® Quality Showcase
- Heart Theaters
- HeartQuarters

# Key Locations



Find key wayfinding maps to easily navigate your way through #AHA22.

Science & Technology Hall Map  
pg. 54-55

McCormick Place Map  
pg. 58-59

Scientific Sessions 2022 Hotel Map  
pg. 62-63

## Abstracts on USB

Lexicon Pharmaceuticals  
Exhibit Booth  
Science & Technology Hall,  
Booth 2404

## AHA Game Yard

Science and Technology  
Hall, South Hall, Level 3,  
Booth 2055

## AHA HeartQuarters

Science & Technology Hall,  
Heart Hub

## AHA Member Celebration

Science & Technology Hall,  
Heart Hub

## AHA Show Management Office

Room S404D

## AHAtv

Grand Concourse Lobby,  
Level 3

## BCVS Council Dinner

McCormick Place  
Convention Center,  
Room S406A

## Braindate Lounge

Science & Technology Hall,  
Heart Hub

## Business Center (UPS)

Grand Concourse, Level 2.5

## Case Theater

See Map for Location

## Celebrate Basic Science Reception

Science and Technology  
Hall, Posters Zone 1

## Chicago Information Booth

Main Entrance to  
McCormick Place  
Convention Center

## Childcare Center

Room N128

## Claim CME

See Registration Hours  
Registration Area,  
North Hall Foyer, Level 3

## Coat and Bag Check

Built In, See map.

## Communication Centers/ Claim CE

Registration Area,  
North Hall Foyer, Level 3

## Council Events

Hyatt Regency McCormick  
Place, Rooms Vary

## Digital Moderated Posters

Science & Technology Hall,  
See Map

## Early Career and Fellows in Training (FIT) Lounge

Science & Technology Hall,  
Heart Hub

## Exhibitor Lounge and Sales Office

Science and Technology  
Hall, Booth 2857

## FAHA Lounge

Science & Technology Hall,  
Heart Hub

## First Aid/Medical Offices

Grand Concourse, Level 2.5

## Get With The Guidelines Quality Showcase

Science & Technology Hall,  
Heart Hub

## Go Red Women in Science and Medicine Lounge

Science & Technology Hall,  
Heart Hub

## Headshot Lounge

Science & Technology Hall,  
Heart Hub

## Health Innovation Pavilion

Science & Technology Hall,  
Heart Hub

## Heart Theater

Science & Technology Hall,  
Heart Hub

## Hotel/Housing Desks

Registration Area,  
North Hall Foyer, Level 3

## Lost and Found

Show Management Office,  
S404D

## Lunch With Legends

McCormick Place  
Convention Center,  
Room S405AB

## Main Event I

Science & Technology Hall,  
See map.

## Main Event II

Room S100A

## Main Event III

Room S100BC

## Mobile Meeting Guide App Help Desk

Grand Concourse, Level 2.5

## Mothers Room

Visit AHA Show  
Management Office,  
Room S404D, for key.

## News Media Center

Rooms S501-S505

## Overflow Area for Programming

Registration Area,  
North Hall Foyer, Level 3  
on Sunday and Monday

## Poster Attendant Booth

See Science & Technology  
Hall Map

## Poster Look-Up Area

See Science & Technology  
Hall Map

## Poster Zones

See Science & Technology  
Hall Map

## Prayer Room

Room N127

## Puppy Snuggles

Science & Technology Hall,  
Booth 2257

## Recharge Lounge

Science & Technology Hall,  
Heart Hub

## Registration

Registration Area,  
North Hall Foyer, Level 3

## Ride Share Pickup/ Dropoff

North Building, Level 1  
(at main entrance of  
convention center)

## Science & Technology Hall (Exhibits)

South Hall, Level 3

## Security Office

N137

## ShopHeart (Association Store)

Registration Area,  
North Hall Foyer, Level 3

## Shuttle Desk & Schedule

South Hall Lobby, Level 1

## Shuttle Pick-Up/ Drop-Off

South Building Lobby,  
Level 1

## Speaker Resource Center

Room N426AB

## Wellness Challenge

Grand Concourse, Level 2.5

# Shuttle Bus Information

Shuttle departs approximately every 20 minutes, subject to traffic and other conditions. Scan QR code for real-time shuttle information.



Note: Scan QR code for Route 7 hotels' scheduled departure times.

## Friday, Nov. 4

6:30-10:30 a.m.	Shuttle from hotels to McCormick Place
10:30 a.m.-5 p.m.	Shuttle between hotels and McCormick Place
5-6:30 p.m.	Shuttle from McCormick Place to hotels


## Saturday, Nov. 5 / Sunday, Nov. 6

6:30-10:30 a.m.	Shuttle from hotels to McCormick Place
10:30 a.m.-6 p.m.	Shuttle between hotels and McCormick Place
6-7:30 p.m.	Shuttle from McCormick Place to hotels

## Monday, Nov. 7

6:30-10:30 a.m.	Shuttle from hotels to McCormick Place
10:30 a.m.-4 p.m.	Shuttle between hotels and McCormick Place
4-6:30 p.m.	Shuttle from McCormick Place to hotels

Estimated one-way travel time is 25-45 minutes, subject to change at any time without notice, based on traffic and other conditions. Please allow ample time to get to/from the hotels and convention center. Departure times are approximate, plan to arrive early and wait at designated boarding area at the Hilton Suites.



Please stop by the shuttle desk at the convention center or call/text KUSHNER & ASSOCIATES at 213-294-5378 with questions, comments or to make an advance reservation for a wheelchair-lift vehicle with tie down or another type of accessible vehicle.

## Hotel Routes and Boarding Locations

### Route 1

**Blackstone Hotel**  
At Hilton Chicago

**Hilton Chicago**  
8th Street entrance

### Route 2

**JW Marriott**  
Curbside on LaSalle Street

**The Palmer House Hilton**  
Wabash Avenue entrance

### Route 3

**Courtyard by Marriott Chicago Downtown River North**  
SE corner of Dearborn and Hubbard before CTA stop

**Renaissance Chicago Hotel**  
Curbside in front

**Royal Sonesta Chicago Downtown**  
At Renaissance Chicago

**Virgin Hotel Chicago**  
At Renaissance Chicago

**The Westin Chicago River North**  
SE corner of Dearborn and Hubbard before CTA stop

### Route 4

**Chicago Marriott Downtown Magnificent Mile**  
SW corner of Ohio and Rush

**Embassy Suites Chicago Downtown**  
Curbside in front

**Hilton Garden Inn Chicago Downtown/Magnificent Mile**  
SW corner of Ohio and Rush

### Route 5

**The Fairmont Chicago**  
At Hyatt Regency Chicago

**Hyatt Regency Chicago (ReSS22 Headquarters Hotel)**  
On Wacker Drive outside East Tower

**Swissotel Chicago**  
At Hyatt Regency Chicago

### Route 6

**Embassy Suites Hotel Chicago Downtown Magnificent Mile**  
At Sheraton Chicago

**Sheraton Chicago Hotel & Towers**  
Curbside on Columbus Drive

### Route 7

Scan QR code at top of the page for Route #7 scheduled departure times

**Hilton Suites Chicago Magnificent Mile**  
Across the street from front entrance

**Sonesta (formerly Residence Inn)**  
At Hilton Suites

### Walking Hotels

No shuttle service provided at these hotels

**Hampton Inn McCormick Place**

**Hilton Garden Inn McCormick Place**


**Hyatt Regency McCormick Place**

**Marriott Marquis Chicago (Scientific Sessions Headquarters Hotel)**




# McCormick Place Map


## SOUTH BUILDING, LEVEL 5




## SOUTH BUILDING, LEVEL 4




## NORTH BUILDING, LEVEL 2




## NORTH BUILDING, LEVEL 4




## MCCORMICK PLACE



## NORTH BUILDING, LEVEL 1





Rooms in blue indicate AHA Scientific Sessions programming locations.

♥ = AED LOCATIONS

# Satellite Symposia

These events are not part of the official Scientific Sessions 2022 as planned by the AHA Committee on Scientific Sessions Program.

## Friday, Nov. 4

### Case Challenges With Antiplatelet Therapy

**Dinner and Registration: 6-6:30 p.m.**

**Symposia: 6:30-8 p.m.**

*Marriott Marquis Chicago, Great Lakes FG Ballroom*

**SPONSOR:** VoxMedia

**SUPPORTER:** AstraZeneca

Register online at [www.symposiareg.com/22211](http://www.symposiareg.com/22211)

## Saturday, Nov. 5

### Making the Call in Heart Failure: Multidimensional Outcomes With SGLT2 Inhibitors

**6-7:30 a.m.**

*Marriott Marquis Chicago, Grand Horizon Ballroom – Section EF*

**SPONSOR:** Global Education Group and Integritas Communications

**SUPPORTER:** AstraZeneca

Register online at <https://www.exchangeeme.com/HFChicago22>

### Breaking Through the Resistance: Innovations Surrounding Resistant Hypertension

**6-7:30 a.m.**

*Marriott Marquis Chicago, Great Lakes Ballroom A-B, Level 2*

**SPONSOR:** Janssen

**SUPPORTER:** TotalCME

Register online at [www.mededotg.com/rHTN](http://www.mededotg.com/rHTN)

### Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis and Management of Myocarditis and Other Cardiac Immune-Related Adverse Events

**6-7:30 a.m.**

*Hyatt Regency McCormick Place, Prairie Room*

**SPONSOR:** PVI, PeerView Institute for Medical Education

**SUPPORTER:** Bristol Myers Squibb

Register online at [PeerView.com/CardioOnc22-Live](http://PeerView.com/CardioOnc22-Live)

### How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure

**6-7:30 p.m.**

*Marriott Marquis Chicago, Grand Horizon Ballroom E*

**SPONSOR:** PVI, PeerView Institute for Medical Education

**SUPPORTER:** Boehringer Ingelheim, Eli Lilly and Company

Register online at [PeerView.com/2022HF-Live](http://PeerView.com/2022HF-Live)

### IV Iron Expert Exchange: Data-Driven Debates on the Revolutionary Role of IV Iron in Heart Failure

**6-7:30 p.m.**

*Marriott Marquis Chicago, Grand Horizon Ballroom G, Level 4*

**SPONSOR/SUPPORTER:** CEC

For more information and to register, visit:

[www.ceconcepts.com/content/iv-iron-expert-exchange](http://www.ceconcepts.com/content/iv-iron-expert-exchange)

### Managing Patients With Recent Worsening Heart Failure With Reduced Ejection Fraction: Keys to Successful Outcomes

**6:30-8 p.m.**

*Marriott Marquis Chicago, Great Lakes FG Ballroom*

**SPONSOR:** VoxMedia

**SUPPORTER:** Cytokinetics, Inc

Register online at [www.symposiareg.com/22210](http://www.symposiareg.com/22210)

### From Cell to Bedside—Transforming the Care of the Cardiac Patient

**7:30-9 p.m.**

*Sable at Navy Pier Chicago, Grand Horizon Ballroom EF*

**SPONSOR/SUPPORTER:** Rush University Medical Center

Register online at <https://www.eventbrite.com/e/from-cell-to-bedside-transforming-the-care-of-the-cardiac-patient-tickets-439003038907>

### ABC's Dr. Walter M. Booker, Sr. Memorial Symposium "Structural Racism and Healthcare Disparity: Cause or Effect?"

**7:30-9 p.m.**

*Marriott Marquis Chicago/Grand Horizon Ballroom, Section A, 4th Floor*

**SPONSOR/SUPPORTER:** Association of Black Cardiologists, Inc.

Register online at [www.cognitofrms.com/AssociationOfBlackCardiologistsInc1/ABCEventsAtAHA22](http://www.cognitofrms.com/AssociationOfBlackCardiologistsInc1/ABCEventsAtAHA22)

---

**Integrating Novel Cardiac Myosin Inhibitors Into the Management of Hypertrophic Cardiomyopathy: Practical Strategies for Diagnosis and Treatment**

**7:30 – 9 p.m.**

*Marriott Marquis Chicago, Grand Horizon Ballroom AB, Level 4*

**SPONSOR:** Answers in CME

**SUPPORTER:** Bristol Myers Squibb

Scan the QR code to register:



---

## Sunday, Nov. 6

**Obesity as a Cardiovascular Risk Factor: Assessment and Management**

**6–7:30 a.m.**

*Hyatt Regency McCormick Place, Jackson Park*

**SPONSOR:** Novo–Nordisk

**SUPPORTER:** Rockpointe

Register online at [www.rockpointe.com/Obesity-CVRiskFactor](http://www.rockpointe.com/Obesity-CVRiskFactor)

---

**Real-World Perspectives on the Under-Diagnosis of Heart Failure in the U.S.**

**6–7:30 a.m.**

*Marriott Marquis Chicago, Grand Horizon Ballroom EFG*

**SPONSOR/SUPPORTER:** Roche Diagnostics

Register online at [https://docs.google.com/forms/d/1\\_YdDe7tUbn1jagJYeJLgqJiU4JCOB9eoEyOrXivG5qQ/viewform?edit\\_requested=true](https://docs.google.com/forms/d/1_YdDe7tUbn1jagJYeJLgqJiU4JCOB9eoEyOrXivG5qQ/viewform?edit_requested=true)

---

**Advances in Imaging and Targeted Management for Cardiac Inflammation: Clinical Progress in Pericarditis**

**6–7:30 p.m.**

*Hyatt Regency McCormick Place, Prairie Room*

**SPONSOR:** Kiniksa

**SUPPORTER:** Medscape

For more information and to register, visit:

<https://na.eventscloud.com/website/44456/>

---

**Transforming the Treatment of Hypertrophic Cardiomyopathy: Key Updates on Sarcomere-Directed Therapies**

**6–7:30 p.m.**

*Marriott Marquis Chicago, Great Lakes Ballroom*

**SPONSOR/SUPPORTER:** Cytokinetics, Inc.

For more information and to register, visit:

[www.medscape.org/symposium/hcm-2022](http://www.medscape.org/symposium/hcm-2022)

---

**Ultrasound Renal Denervation (uRDN)—Leading With Evidence and Preparing for What Comes Next**

**6–7:30 p.m.**

*Hyatt Regency McCormick Place, Jackson Park ABC*

**SPONSOR/SUPPORTER:** ReCor Medical

---

**Expert Perspectives and Discussions: What You Need to Know About Optimizing Cardiorenal Outcomes With Novel Nonsteroidal MRAs**

**7:30–9 p.m.**

*Marriott Marquis Chicago, Great Lakes EF Ballroom*

**SPONSOR/SUPPORTER:** Cardiometabolic Health Congress

Reserve your seat at <https://www.cardiometabolichealth.org/aha2022>

---

**JAMA Network Reception (Invitation-only event)**

**7:30–9 p.m.**

*Hyatt Regency Chicago, Crystal C*

**SPONSOR/SUPPORTER:** JAMA Network

---

## Monday, Nov. 7

**Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering Therapies**

**6–7:30 a.m.**

*Hyatt Regency McCormick Place, Regency Ballroom CDE, Level 2*

**SPONSOR:** PVI, PeerView Institute for Medical Education

**SUPPORTER:** Novartis

Register online at [https://lrn.peerview.com/150207909\\_1/150207909\\_1\\_p1/stage1reg?Promocode=980&AudienceID=AHA&ProjectNumber=150207909\\_1&CountryID=US](https://lrn.peerview.com/150207909_1/150207909_1_p1/stage1reg?Promocode=980&AudienceID=AHA&ProjectNumber=150207909_1&CountryID=US)

# #AHA22 Hotels

Below are Chicago hotels, their addresses and the distance from McCormick Place. Locations are noted as well on the map to the right.

- |  |  |   |
|--|--|---|
| <p><b>1 Blackstone Hotel</b><br/>636 S. Michigan Ave.<br/>1.9 miles</p> <p><b>2 Chicago Marriott Downtown Magnificent Mile</b><br/>540 N. Michigan Ave.<br/>3.4 miles</p> <p><b>3 Courtyard by Marriott Chicago Downtown River North</b><br/>30 E. Hubbard St.<br/>3.3 miles</p> <p><b>4 Embassy Suites Chicago Downtown</b><br/>600 N. State St.<br/>3.5 miles</p> <p><b>5 Embassy Suites Hotel Chicago Downtown Mag Mile</b><br/>511 N. Columbus Drive<br/>3.0 miles</p> <p><b>6 Hampton Inn McCormick Place</b><br/>123 E. Cermak #100<br/>0.4 miles</p> <p><b>7 Hilton Chicago</b><br/>720 S. Michigan Ave.<br/>1.8 miles</p> <p><b>8 Hilton Garden Inn Chicago Downtown/Magnificent Mile</b><br/>10 E. Grand Ave.<br/>3.4 miles</p> | <p><b>9 Hilton Garden Inn McCormick Place</b><br/>123 E. Cermak #300<br/>0.4 miles</p> <p><b>10 Hilton Suites Chicago Magnificent Mile</b><br/>198 E. Delaware Place<br/>4.1 miles</p> <p><b>11 Hyatt Regency Chicago**</b><br/>151 E. Wacker Drive<br/>3.4 miles</p> <p><b>12 Hyatt Regency McCormick Place*</b><br/>2233 S. Martin Luther King Drive<br/>0 miles</p> <p><b>13 JW Marriott</b><br/>151 W. Adams St.<br/>2.6 miles</p> <p><b>14 Marriott Marquis Chicago*</b><br/>2121 S. Prairie Ave.<br/>0.1 mile</p> <p><b>15 Renaissance Chicago Hotel</b><br/>One W. Wacker Drive<br/>3.5 miles</p> <p><b>16 Royal Sonesta Chicago Downtown (Wyndham Grand Chicago Riverfront)</b><br/>71 E. Wacker Drive<br/>2.8 miles</p> | <p><b>17 Sheraton Chicago Hotel &amp; Towers</b><br/>301 E. North Water St.<br/>2.9 miles</p> <p><b>18 Sonesta (formerly Residence Inn)</b><br/>201 E. Walton Place<br/>4.0 miles</p> <p><b>19 Swissotel Chicago</b><br/>323 E. Wacker Drive<br/>2.9 miles</p> <p><b>20 The Fairmont Chicago</b><br/>200 N. Columbus Drive<br/>3.0 miles</p> <p><b>21 The Palmer House Hilton</b><br/>17 E. Monroe St.<br/>2.5 miles</p> <p><b>22 The Westin Chicago River North</b><br/>320 N. Dearborn St.<br/>3.2 miles</p> <p><b>23 Virgin Hotel Chicago</b><br/>203 N. Wabash Ave.<br/>2.7 miles</p> |
|--|--|---|

\* Headquarter Hotel  
\*\* Resuscitation Science Symposium (ReSS)

● Hotel names in red denote hotels with symposia



## Thank You to Our Sponsors

The American Heart Association is grateful for the continued support and generosity of the following companies:

- AccurKardia, Inc
- AHA Doctors with Hearts
- AHA Journals
- AHA Lifelong Learning
- American Academy of Sleep Medicine
- Amgen Inc.
- AstraZeneca
- Aventyn Inc.
- Bayer HealthCare Pharmaceuticals Inc
- Biobeat Technologies, LTD
- BodyPort Inc.
- Boehringer Ingelheim Corporation
- Bristol-Myers Squibb
- Cardiometabolic Health Congress
- Creative Educational Concepts
- CSL Behring, LLC
- Cytokinetics, Inc
- Edwards Lifesciences LLC
- Elucid BiImaging, Inc.
- High Enroll, LLC
- Impulse Dynamics
- Intellia Therapeutics, Inc
- Janssen Pharmaceuticals, Inc.
- Kestra Medical Technologies
- Kiniksa Pharmaceuticals
- Level Ex
- Lexicon Pharmaceuticals, Inc
- MediWhale
- Medtronic
- Merck & Co.
- Movano, Inc.
- Moving Analytics, Inc
- Novartis Pharmaceuticals Corporation
- Novo Nordisk
- Ognomy
- Pfizer Inc
- Sanofi
- Wolters Kluwer
- Xandar Kardian Inc

Educational support for AHA Scientific Sessions is provided by:

- AstraZeneca
- Bristol Myers Squibb/Pfizer Alliance
- Chiesi USA, Inc.
- Cytokinetics, Inc.
- Medtronic
- Merck & Co.
- Pfizer Inc.

# Thank You FAHAs

A heartfelt **THANK YOU** to all of our **Fellows of the American Heart Association (FAHAs)**! Your dedication and contributions define commitment to excellence.

Stop by the Heart Hub and visit with other fellows of AHA in the **FAHA Lounge**.

Saturday, Nov. 5 | 9 a.m.-4:30 p.m.

Sunday, Nov. 6 | 9 a.m.-5 p.m.

Monday, Nov. 7 | 9 a.m.-3 p.m.



American  
Heart  
Association.



Scientific  
Sessions

[ScientificSessions.org](https://www.ScientificSessions.org)



American  
Heart  
Association.

# Abstract Submissions Open April 2023

November 11-13, 2023  
Philadelphia, PA

REGISTRATION OPENS  
SUMMER 2023



# Braindate at #AHA22

Looking to meet great people, learn about new things, and spark meaningful conversations? It all starts with a Braindate.

Braindates are knowledge-sharing conversations that you book with others to have one-on-one or in small groups in the Braindate Lounge. They're the best way to brainstorm, solve challenges, share expertise or experiences while connecting with new (brilliant!) people.



## Here's how to access the Braindate platform:

1. **Log into Braindate:** Create your profile link directly from the mobile app first page in the Braindate tab.
2. **Explore the Topic Market:** Post, search, or filter topics of interest with available space.
3. **Create topics:** Post Braindate topics you would like to discuss. Share your knowledge, experiences, and expertise.
4. **Book a Braindate:** Send invitations to meet others to discuss their topics in a one-on-one or small group conversation.
5. **Time to Meet Up:** Your Braindate will take place in the Braindate Lounge in the Heart Hub (Science & Technology Hall) during show hours; join a 30-minute one-on-one or small 45-minute group up to a six-person session.
6. **How to Host:** A Braindate is not a presentation; it is a conversation that stems from a shared interest.

### Host Tips:

- a. Make sure everyone introduces themselves and contributes.
- b. Ask the participant(s) what interested them about the topic.
- c. Be transparent and honest about your experience related to the topic: You don't need to be an expert to lead a Braindate.
- d. Share contact information!

### Questions?

Need advice on creating a compelling Braindate topic or finding relevant topics? Have questions about how to use the Braindate platform?

Learning Concierges will support you in making the most of your experience. Don't hesitate to connect with one of them via the platform in the mobile app or on-site in the Braindate Lounge.



## Download the AHA Journals' Publishing Guide & Overview Today



Includes:

- Impact metrics for each AHA journal
- A concise overview of publishing requirements and policies
- Unique journal features and offerings

**Download for free today  
and submit your research**

[AHAjournals.org/all-submission-sites](https://AHAjournals.org/all-submission-sites)

